CEO Healthcare Symposium
A passionate advocate for the healthcare industry, Andrew co-founded Priority Private Care in 2016 to revolutionize the care experience. Priority Private Care’s model challenges the status quo, offering consumers a healthcare alternative that is smart, sensible, simple, and human. Prior to that, he was a healthcare investor and analyst for over 10 years at Generation IM, Morgan Stanley and Merrill Lynch. He has consulted for numerous health systems around the globe to create more effective and efficient delivery models. Andrew holds an MBA from London Business School and a BA from Columbia University.
Mr. Ritter co-founded Ritter Pharmaceuticals, Inc. (RTTR) a publicly traded biotech company focused on developing treatments for digestive diseases. Upon his own personal affliction with lactose intolerance, he spearheaded the development of its lead compound, RP-G28, which has the potential to become the first FDA-approved treatment for lactose intolerance. The therapeutic is currently in Phase 3 clinical trials. Mr. Ritter holds over a dozen patents and has co-published articles in the Proceedings of the National Academy of Sciences, Nutrition Journal, Food Technology, among others. In addition, Mr. Ritter is a guest lecturer of entrepreneurship at various business schools throughout Los Angeles, including: UCLA Anderson School of Management, USC Marshall School of Business and Pepperdine's School of Business and Management. Mr. Ritter has been an active leader in his community, including being appointed as a Los Angeles City Commissioner to the Commission for Children, Youth and Their Families from 2000-2002 (the youngest appointed Commissioner in Los Angeles history). Mr. Ritter holds a Bachelor of Arts Degree in Political Science and a minor in Business from the University of Southern California and was a member of the 2002 Pac-10 Champion baseball team. In addition, Mr. Ritter received his MBA from The Wharton School, University of Pennsylvania."
Dr. Anish Bhatnagar is the Chief Executive Officer of Soleno Therapeutics, a company focused on the development of therapeutics for rare diseases. He is a physician with twenty years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania. Soleno’s lead product is for the treatment of Prader Willi Syndrome.
Anthony Spero has more than 20 years of experience in healthcare operations and business development within the acute and post-acute health care industry. As an operator in the post-acute space Mr. Spero has managed Skilled Nursing and Long Term Care Facilities, Independent and Assisted Living Facilities, CCRC’s and Long Term Acute Care Hospitals. Currently as President of Ascend Health, he leads the company’s multi-state operation focused on providing best-in-class hospice, home health and concierge home care services. Previously, Mr. Spero worked as the National Vice President of Business Development at Golden Living. Mr. Spero received his Master’s Degree in Healthcare Administration and his MBA in Finance from Suffolk University. He is a licensed nursing home administrator and is most proud of his employment as a certified nursing assistant completed very early on in his healthcare career. In 2015 Mr. Spero was a speaker at the AHCA Quality Symposium and the Home Care Leadership Summit and presented on the topic of “People Centered Care”.
Dr. Ashok Rai is President and CEO of Prevea Health, the largest multi-specialty group practice in
northeast Wisconsin. Dr. Rai has a personal commitment to the wellness of this community and
continues to inspire others to live healthy. His association with Prevea Health began in 2001 when he joined Prevea’s partner hospital, HSHS St. Mary’s Hospital as the Medical Director for Hospitalist
Services. During the past 16 years, Dr. Rai has also served as St. Mary’s Physician Quality Director and
Prevea’s Associate Medical Director of Operations, Senior Vice President, and Chief Medical Officer. Dr.
Rai’s passion to redesign healthcare extends nationally, and he was recently named as the Chair Elect for the Board of Directors of the AMGA—a national association of medical groups leading the
transformation of health care in America. His passion for wellness has led Prevea to embrace the Patient
Centered Medical Home model of care, bringing patient-centric care beyond the clinic and directly out
into the community and workplace. Prevea’s customized care educates and empowers individuals to lead a healthy and fit lifestyle, thereby improving the total wellness of the region.
August J. Moretti is Chief Financial Officer of Depomed, Inc. (NASD: DEPO), a
specialty pharmaceutical company. Previously he was Chief Financial Officer of
Alexza Pharmaceuticals, a publicly held pharmaceutical company, and Chief
Financial Officer of Alavita, a privately held biotechnology company. Mr. Moretti
holds a BA in Economics from Princeton University and a JD from Harvard Law
Barbara Walczyk Joers
Chief Executive Officer and President
Barbara Walczyk-Joers became Gillette Children's Specialty Healthcare’s chief executive officer
in late 2013. As the nation’s first hospital dedicated to serving children who have disabilities,
Gillette provides specialized care to children who have complex, rare or traumatic conditions
affecting the neurological, muscular and/or skeletal systems.
In her time at Gillette, Joers has implemented a focused and strategic approach to system
improvement that cultivates Gillette’s expertise in core service areas and emphasizes
collaboration with healthcare systems across the country to improve access to niche
subspecialty care. Amidst a time of rapid rules and policy changes, Joers has led Gillette to
advocate at the state and federal level for children and adults who have disabilities and the
importance of access to coordinated specialty care for this population.
With more than twenty years of experience in healthcare, Joers has a focus on performance and
change management. She has experience in academic health centers, both adult and pediatric
services, community health systems and independent children's hospitals. Earlier in her career
Joers also served at a professional services firm where, in addition to her healthcare client work,
she was part of an appointed team that developed methodologies for transformation
A recognized thought leader in healthcare, Joers serves on the Board of Directors of Children’s
Miracle Network Hospitals and on committees for other national organizations supporting
children’s healthcare. She has received several recognitions and awards, including Modern
Healthcare’s “Up and Comer’s” award and Minneapolis / St. Paul Business Journal “Women in
Business” award. Joers is a graduate of Marymount University (VA) and holds a Masters in
Health Services Management and Policy from the George Washington University (DC). She
and her family currently reside in St. Paul, Minnesota.
Twitter: @BarbaraCEO and @GilletteChildrn
LinkedIn: Barbara Walczyk Joers
Facebook: Gillette Children’s
Benjamin Edmands is a Managing Partner and Co-Founder of Consonance Capital Partners. Prior to founding CCP, he was a Managing Director at JPMP, where he co-led the Healthcare Group. Benjamin joined JPMP in 1993 and served on numerous boards, including Big Rock, CareMore, DJO, LHP Hospital Group, MedQuest, National Surgical Care, and Warner Chilcott, Inc. He also serves on the board of Enclara Pharmacia, Bako Integrated Physician Solutions, Mount Sinai’s Children’s Environmental Health Center and is on the Executive Council of the Harvard School of Public Health. Benjamin holds a BA from Colgate University and an MBA from Columbia Business School.
Mr. Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became the top performing IPO; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the Elacestrant oncology program. Prior to joining Radius, Mr. Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.
Bonnie H. Anderson is Chief Executive Officer and Chairman of the Board of Veracyte, a pioneering
genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in
healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly
procedures. Her career spans over 30 years in regulated diagnostics and life science markets. Ms.
Anderson cofounded Veracyte in 2008 and served as the company’s President and Chief Executive
Officer until 2016, when she was also appointed Chairman of the Board. She took the company public in
2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests
are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of
thousands of patients avoid unnecessary surgery.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-
stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board
of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a
trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana
University of Pennsylvania with a Bachelor of Science degree in Medical Technology and in 2012 was
honored with a “Distinguished Alumni” award. In 2017, Ms. Anderson received the prestigious Wallace H.
Coulter Award for Healthcare Innovation and was also named one of FiercePharma’s “Fiercest Women in
Life Sciences.” In 2015, Fast Company magazine featured Ms. Anderson on its “100 Most Creative
People in Business” list. She was named one of the “Most Influential Women in Bay Area Business”
(2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times,
and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).
CARL SPANA, Ph.D., co-founder of Palatin, has been the Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly-held pharmaceutical company, where he was involved in scientific research in the field of immunology. He was previously a member of the board of the life science company AVAX Technologies, Inc.
Dr. Spana received his Ph.D. in molecular biology from the Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
Charles P. Theuer, M.D., Ph.D. – Director, President and Chief Executive Officer – Dr.
Theuer has been CEO and President of TRACO, and a Director of TRACON Pharmaceuticals
(NASDAQ: TCON) since 2006. Prior thereto, from October 2004 to July 2006, Dr. Theuer was
Chief Medical Officer at TargeGen Inc., where he led the development of small molecule kinase
inhibitors in oncology (including fedratinib, a jak2 inhibitor), ophthalmology and cardiovascular
disease. From October 2003 to October 2004, Dr. Theuer was the Director, Clinical Oncology at
Pfizer, where he led the clinical development of Sutent® (sunitinib maleate) in kidney cancer;
Sutent® was approved by the U.S. Food and Drug Administration in January 2006 for treating
advanced kidney cancer. Prior thereto, Dr. Theuer held senior positions at IDEC
Pharmaceuticals, from June 2002 to October 2003, and the National Cancer Institute developing
other agents, including small molecules and monoclonal antibody therapies. Dr. Theuer holds a
B.S. degree from the Massachusetts Institute of Technology, an M.D. degree from the University
of California, San Francisco and a Ph.D. degree from the University of California, Irvine. He
completed a residency in general surgery at Harbor-UCLA Medical Center and was Board
Certified in general surgery in 1997. Dr. Theuer held academic positions at the National Cancer
Institute (NCI) and at the University of California, Irvine, where he was a member of the Division
of Surgical Oncology. His previous research involved immunotoxin and cancer vaccine
development, translational work in cancer patients, as well as gastro-intestinal cancer
Christian Seale is an early stage investor and entrepreneur committed to transforming the health and lives of billions. He has built Miami's first digital health innovation program and fund supported by the Knight Foundation, Miami Children’s Hospital, and private healthcare investors. Before his work in Miami, Christian was a founding member of Equitable Origin, the world’s first certification for responsible energy production. He is a Founding Member of NextGen Venture Partners in Boston and previously worked for consumer-only VC firm Maveron, Goldman Sachs and Teach for America. Christian is a World Economic Forum Global Shaper, a Fulbright Scholar, and an active contributor to Univision and TechCrunch. Christian earned his MBA from Harvard Business School and is also a graduate of Brown University.
Dr. Xu has served on Cesca’s board of directors since March 2016, and was appointed chairman and interim chief executive officer in November 2016 and CEO in August 2017. He brings to Cesca over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a China-based diversified life sciences holding company and is currently the principal shareholder of Cesca. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).
Ms. Cindy Bo has worked in healthcare strategy for over 20 years, ranging across the provider, payor and life sciences sectors.
She is named by the Becker's Hospital Review in 2016 and 2015 as one of the top 130 women hospital and health system
leaders to know in the United States.
Ms. Bo has expertise in strategic planning, business development, mergers and acquisitions and finance transformation. She has
worked collaboratively with executive leaders across the healthcare industry to improve the viability of healthcare delivery and
management of population health. Currently, she is the Chief Strategy & Business Development Officer for Nemours Children’s
Health System, Alfred I. duPont Hospital for Children. At Nemours, she manages the strategies and business development
processes in support of new growth and integration opportunities for both the hospital and practice in the Delaware Valley. She
also develops new strategic partnerships with clinical partners and other healthcare vendors. Ms. Bo drives the business
planning process for clinical services and programs. She is also co-leading the Nemours Value-Based Services Organization, as
Nemours transitions to value.
Prior to joining Nemours, she was a Senior Manager and an Ellen Gabriel Fellow at Deloitte, in the Healthcare M&A Practice. At
Deloitte, she led the strategic transformation for large regional health systems; led the M&A deals for national and regional
health plans, health systems and pharmacy benefit managers; and led revenue cycle management for major provider systems
around the US. Ms. Bo was also a Director at Novartis, leading the Business Planning & Analysis, Center of Excellence where she
managed the strategic planning for Novartis’ North American Primary Care portfolio.
Ms. Bo is a Malcolm Baldrige Executive Fellow and a graduate of the Disparities Leadership Program, working with
Massachusetts General Hospital. She is also an Aspen Institute Scholar. She is also an appointed Member by Governor John
Carney on the Delaware Economic and Financial Advisory Council. Ms. Bo is currently serving on several distinguished Boards.
She is a Board Member for the Clinic for Special Children in Strasburg, PA, the American Lung Association for the Mid-Atlantic
and the Delaware Center for Health Innovation. She is an Executive Team Member of the United Way of Delaware Young
United Professionals. She currently volunteers for the Nemours Children’s Health System, Alfred I. duPont Hospital for Children
and the Ronald McDonald House of Delaware. In the past, she has volunteered for City Year in Philadelphia, PA; Dekalb
Community Service Board in Atlanta, GA; and The William J. Clinton Foundation in New York, NY.
On the personal side, she is an avid runner, writes children’s stories, creates greeting cards and enjoys spending time with her
husband, David, and sons, Matthew (age 18) and Lucas (age 4).
Ms. Bo has earned her MBA, with high distinction and honors, from Columbia Business School and her BS, summa cum laude,
from Binghamton University School of Management.
Dr. Svendsen has served as Forward Pharma’s Chief Executive Officer since March 2017.
Within Forward Pharma, his previous role as Executive Vice President included
responsibility for corporate functions, portfolio strategy, regulatory interactions and
medical and scientific input across all phases of clinical trials. Prior to joining in 2015, he
held positions of increasing seniority in the Danish pharmaceutical company Novo Nordisk
A/S, including roles of Global Medical Director for Victoza® (liraglutide) and for Saxenda®
in its regulatory and pre-launch phase for weight management, supporting a successful
FDA advisory committee meeting and finally FDA and EMA approval. From 2007 to 2009,
he worked as a Medical Analyst in Nordic Biotech Advisors ApS, dealing with due diligence
of potential investment opportunities. He is a Medical Doctor from University of
Copenhagen in 2003, and additionally completed a PhD in sarcoidosis pathobiology in
2009. He has worked in several countries with a clinical background mainly in internal
medicine, and is a recipient of a Young Investigator Award from the Foundation for
Sarcoidosis Research in 2009. Dr. Svendsen is an author of 27 publications in international,
peer-reviewed journals and >50 abstracts presented at international congresses on
pathobiology of sarcoidosis, methods in molecular biology, and medical treatment of
diabetes and obesity.
Daniel Blum has served as President and CEO of Phelps Memorial Hospital Center since December 2014. Prior to joining Phelps as Senior Vice President in 2009, Mr. Blum served as Senior Vice President of White Plains Hospital Center, Vice President of Operations of Stellaris Health Network, and Operations Manager at St. Vincents Hospital and Medical Center in New York City. Mr. Blum began his healthcare career as a paramedic and paramedic instructor in New York City and worked at several New York City hospitals in a clinical and administrative capacity. Mr. Blum holds a bachelors degree in philosophy and a masters degree in healthcare administration, both from New York University. He is a member of the American College of Healthcare Executives and Medical Group Management Association. Mr. Blum is also Chairman of the NYS Department of Health Emergency Medical Advisory Council. Mr. Blum serves as collaborating administrative executive on Phelps Graduate Medical Education Committee and Chairman of the hospitals affiliated child care center.
Dan Greenleaf has over two decades of relevant experience in senior leadership positions in the healthcare industry. He is currently serving as President and CEO of BioScrip, Inc., a leading national provider of infusion and home care management solutions. Dan also is a member of BioScrip’s Board of Directors.
Dan served as Chairman and CEO of Home Solutions, a leading provider of home infusion services to patients suffering from chronic and acute medical conditions, from December of 2013 to September of 2016, when Home Solutions was acquired by BioScrip.
Previously he served as President and CEO of Coram Specialty Infusion Services, as well as Chief Operating Officer for Apria Healthcare Group Inc. He joined Apria/Coram in April of 2008 and led Coram to become the industry leader in home infusion and one of the top-performing healthcare companies in the U.S. Under his leadership Coram grew its revenue organically from $600mm to $1.2B (12.5% CAGR); its earnings improved from 4.7% to 13.3% (an increase of more than 250%) and the valuation of the company increased from $350mm to $2.1B.
Prior to joining Apria/Coram, Dan served as President and Chief Executive Officer for VioQuest Pharmaceuticals, a publicly traded biopharmaceutical company. Additionally, Dan was the President of U.S. Operations for Celltech Biopharmaceuticals, prior to its sale to UCB in 2004 for $2.7 billion. Dan also held senior leadership roles with Nabi Pharmaceuticals and Schering-Plough Corporation.
Dan serves on the University of Miami's Health Sector Management and Policy Board, Denison University's Board of Advisors, Rotech Healthcare’s Board, Gryphon Investor's Executive Advisory Board (GEAB) and is a past board member for the National Home Infusion Association (NHIA). He has also been a member of the international group, Young President's Organization (YPO), since 2004. He has also been a guest lecturer on leadership at Wharton School of the University of Pennsylvania and University of Miami School of Business Administration.
A graduate of Denison University with a Bachelor of Arts (B.A.) in Economics, Dan also holds a Master of Business Administration (M.B.A.) in Health Administration from the University of Miami. A military veteran, Dan was a captain and navigator in the United States Air Force and served in Operation Desert Storm.
Dan Murrey is an Orthopedic Spine Surgeon and CEO of Transformant Healthcare solutions (THS).
Dan previously served as CEO of OrthoCarolina, one of the largest orthopedic practices in the country with 160 physicians and 1400 employees throughout the Piedmont of western North Carolina. As CEO, he led efforts in quality improvement, data management, corporate compliance, customer service and contracting innovation. He is also an active researcher and educator, and is a patent-holder and developer of multiple spine care devices.
Transformant Healthcare Solutions (THS) is a management services company that partners with independent physician practices in order to transform the delivery and financing of healthcare, bringing a platform to lower cost of care, improve patient outcomes and enhance the patient experience.
In addition to his role as a physician leader, Dan serves on a number of nonprofit and healthcare boards and speaks about healthcare transformation throughout the country.
The founder and former CEO of Cytovia’s parent company Immune Pharmaceuticals until April
2017, Daniel Teper continues to bring a unique combination of commercial and drug
development experience. Dr. Teper continues to be a member of Immune’s Board of Directors,
Earlier in his career, Dr. Teper was the Managing Director for North America at Bionest
Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology
companies and previously a New York based Partner at ISO Healthcare Consulting (now part of
Deloitte Monitor). Dr. Teper started his career at Novartis Global Headquarters in Basel and
then in the US where he had growing responsibilities in sales, marketing, and new product
Dr. Teper held senior executive positions in Europe, first at GSK as Head of Commercial
Operations for Glaxo France and then as President of Laboratoires Delagrange through the
acquisition by Synthelabo (now part of Sanofi). He then became Global President of HAVAS
Health, a leading marketing and communication group, where he helped launch multiple
industry blockbusters. Dr.Teper was a cofounder of Novagali, which was acquired by Japan’s
Dr. Teper holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA
David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics (NASDAQ: EBIO), Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, LS9 (acquired by Renewable Energy Group) and Indigo. Prior to Flagship, David received an MD from Harvard Medical School and a PhD from the MIT Biological Engineering Division, working in the laboratories of Professors Ram Sasisekharan and Bob Langer, completing the dual degree in just over 5 years.
David currently serves on the Leadership Council of the United Nations Sustainable Development Solutions Network. He is currently on the Boards of the Hackley School and the Juventas New Music Ensemble, and has served on the MIT Corporation, its Board of Trustees as well as the Boston Philharmonic Orchestra. David was elected a 2014 Young Global Leader by the World Economic Forum.
Previously, David was named the Innovator of the Year by Technology Review, and received the prestigious Lemelson-MIT Student Prize for invention and innovation. He was also selected by the US State Department as 1 of 12 Innovators Helping to Reshape Reality.
Prior to co-founding PMV Pharma with biologists Arnold Levine and Thomas Shenk, Dr. Mack was a general partner at Alta Partners from 2002 to 2013. His first investment was Angiosyn (acquired by Pfizer in 2005) where he was a Director and CEO. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003).
From 1994 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) Invention Group at Cetus (now Novartis) in the mid 1980s. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 26 issued US patents. Dr. Mack was an American Cancer Society Postdoctoral Fellow in microbiology and immunology at Stanford University School of Medicine. He received his Ph.D. from the University of Chicago, where he was a Howard Hughes Fellow in Molecular Genetics and Cell Biology, and a B.A. in Molecular Biology from the University of California, Berkeley.
Douglas Fambrough is a co-founder of Dicerna Pharmaceuticals and joined the company as CEO in May 2010. Prior to joining Dicerna, Dr. Fambrough spent over a decade as a biotechnology venture capitalist with Oxford Bioscience Partners, one of Dicerna’s investors. At Oxford, he specialized in financing innovative life science technology companies such as the first generation RNA interference company, Sirna Therapeutics (acquired by Merck). Among his other investments are high-throughput DNA sequencing pioneer Solexa (acquired by Illumina); Xencor, which engineers antibody Fc domains to enhance drug properties; Rib-X Pharmaceuticals, a developer of antibiotics against multi-drug resistant pathogens; and Solstice Neurosciences (acquired by US WorldMeds). Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). Dr. Fambrough graduated from Cornell University and holds a Ph.D. in genetics from the University of California, Berkeley.
Dunston Almeida is a Fortune 25 executive with experience in global technology and healthcare investing at leading organizations, including head of Emerging Markets strategy at Medco/Express Scripts, a $100+ billion Pharmacy Benefits Manager.
He is currently Executive Vice President of Strategy and Business Development at eviCore Healthcare, the largest value-based care company covering 100 million members, and over 100 major Plans and Health Systems across the US. He focuses on M&A, investments and partnerships working with the Board of Directors on eviCore's Strategy Council. Focus areas include advanced analytics, consumer engagement, cognitive computing and machine learning, post-acute care, payment integrity and outcome-based payments.
He has advised major corporations and private equity firms on issues of strategy, change and innovation around population health, value-based care and health care reform. Dunston also supports the formulation of eviCore's public policy strategies in Washington DC.
He has worked on deals across the healthcare spectrum, including HCIT, consumer-driven health, CROs, oncology, home infusion, specialty pharma, Medicare/Medicaid and has completed over $30 billion of M&A transactions in North America, Europe, Latin America and Asia with extensive experience across the entire capital structure.
He graduated from Cornell University with a degree in Electrical Engineering at the age of 20.
Eddie Moradian received his PhD in biotechnology from the Swiss Federal Institute in Zurich, Switzerland. Since 1987, he has been a founder or co-founder of a series of companies in the biotechnological, pharmaceutical and diagnostic industries with presence in Europe, US and Israel.
At MD Biosciences, he leads a group of companies, each individually focused on drug development, preclinical contract research services, CLIA clinical biomarker diagnostic services, and early stage investment in other promising, emerging companies.
Most recently, Eddie was a co-founder of and is serving as co-CEO of Incubology, LLC, a state of the art multi-technological incubator facility with over 50,000sqf of built, turn-key ready laboratory and high tech space located near Saint Paul, MN.
Fatima Paruk, MD, MPH, is the Chief Medical Officer at Allscripts Analytics. Recently recognized as one of the Most Powerful Women in Health IT by E&Y and Health Data Management, along with being named one of Becker’s Rising Stars Under 40, she provides medical leadership to a world-class team to develop, design and deploy predictive models to improve population health. She is a physician and public health specialist that has been extensively involved in health systems, and global surgical initiatives. In addition to her executive role, Fatima remains committed to disaster response.
Dr. Parietti is the co-founder and CEO of Multiply Labs, a healthcare startup focused on personalized medicine. Multiply Labs has developed robotics technology to 3D print personalized medication capsules, tailor-made around the needs of each individual. By containing several independent compartments, each capsule can be personalized with custom quantities of active ingredients and release times. The goal is to combine all the medications a person needs into a single daily pill.
Multiply Labs’ manufacturing facility in San Francisco is the first robotic production line to be GMP-compliant and approved to ship 3D printed capsules in the US. The launch product of the company, a personalized supplement capsule, is already being shipped to customers nationwide.
Dr. Parietti holds a PhD in mechanical engineering from the Massachusetts Institute of Technology. Prior to his research at MIT, Dr. Parietti has worked on advanced robotics at the Carnegie Mellon University, the Polytechnic University of Milan (Italy) and ETH Zurich (Switzerland). Dr. Parietti’s research in the field of robotics and pharma tech has been awarded with the MIT Mechanical Engineering De Florez Design Award (2013) and with the 2015 Best Paper Award in the Journal of Drug Delivery Science and Technology.
Garry Pezzano serves as Senior Vice President of Clinical Practice for Genesis Rehab Services. Under his
leadership, the Clinical Practice department has taken a significant role in supporting the company's
operations and driving the way clinical care is delivered. A licensed speech-language pathologist, Garry
brings more than 20 years of clinical and managerial experience to Genesis. He has held a number of
leadership positions with national rehabilitation providers, always maintaining a clear clinical focus.
Garry is active in his professional associations, including the American Speech-Language- Hearing
Association (ASHA), the New Jersey Speech-Language- Hearing Association, the American Occupational
Therapy Association (AOTA), and the American Association for Respiratory Care (AARC). He currently
serves as Immediate Past President for the National Association for the Support of Long Term Care
(NASL), and formerly served as chair of its Medical Services committee and Board Secretary and faculty
to the PACCR (Post-Acute Care Center for Research). Garry has served on workgroups with the
American Health Care Association (AHCA) and Leading Age, meeting with the Centers for Medicare and
Medicaid Services (CMS) and MedPac in support of projects to improve access to rehabilitation therapy
services for older adults.
Garry received a Bachelor of Science in Communication and Speech-Language Pathology from Trenton
State College, a Master of Science in Speech-Language Pathology, and a Master of Business
Administration from Rutgers University. He has also completed Advanced Topics in Healthcare from
Harvard University's School of Public Health and Wharton Business School, and is a certified green belt
in Lean Sigma. Garry served a Residency in China, Vietnam and Taiwan; studying public health and
administration and recently visited Denmark as part of the country’s Healthcare Delegation.
Gary Cohen is Executive Vice President and President, Global Health and Development
at BD (Becton, Dickinson & Co). Mr. Cohen is also a board director of the Perrigo
Company, CDC Foundation and UNICEF USA, board co-chair of GBCHealth, and board
chair/founder of Together for Girls. He previously served on the UN Commission on
Life Saving Commodities for Women and Children and presently serves on the Scientific
Advisory Board of Grand Challenges Canada.
Mr. Cohen and BD engage in extensive cross-sector collaboration to address unmet
health needs globally, working with international agencies, governments and non-
government organizations, focused on specific health goals such strengthening clinical
and laboratory practices, safely immunizing children, addressing infectious and non-
communicable diseases, reducing maternal and newborn mortality, combating
antimicrobial resistance and improving safety for health workers and patients. He
frequently serves as an expert speaker and advocate on advancing health and human
rights, in various venues including the United Nations, Vatican, World Bank, World
Health Assembly, U.S. Department of State and World Economic Forum-Davos. He has
been honored for his humanitarian work by MESAB (Medical Education for South
African Blacks), B’nai B’rith International, UNICEF USA, the Dikembe Mutombo
Foundation, the American Jewish Committee and the Nymbani Home for HIV positive
children in Kenya. Mr. Cohen holds B.A. and an M.B.A. degrees from Rutgers
University and previously served on the university’s board of trustees. In 2016 he was
named a Rutgers 250 Fellow in association with the university’s 250 th anniversary.
Dr. Geert Cauwenbergh was appointed president and CEO of RXi Pharmaceuticals Corporpation in April 2012. Prior to joining RXi,
Dr. Cauwenbergh served as chairman and CEO of Barrier Therapeutics Inc., a publicly traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson's Skin Research Center, he was responsible for the worldwide research and development of all skin care products for Johnson and Johnson's consumer companies. He is a member of the board of directors of Phosphagenics and Moberg Pharmaceuticals. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as chairman of the board of trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his doctorate in medical sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.
Gregory Solometo co-founded Alliance Homecare in 2006 and serves as the Chief Executive Officer where he oversees the day-to-day operations and strategy. Gregory started the company after he took care of his grandmother for five years when she was suffering from Alzheimers and created The Grandma Rule? hiring philosophy. Gregorys firsthand experience of searching for caregivers showed him that there were limited resources that met his high level of standards of client care and customer satisfaction. Since that time, Gregory has been committed to providing all clients with an elite and highly qualified team of healthcare professionals that exceed industry standards. Prior to starting Alliance Homecare, Gregory has worked primarily in the financial services industry. Most recently, he worked as a Lean Process Engineer at Deutsche Bank where he provided strategic consulting services to various divisions of the Investment Banking structure and its operations in the US and abroad. Gregory graduated from Emory University in 1995.
Harel is a seasoned executive and entrepreneur in the health care space, with an
extensive and proven track record. Harel brings over 17 years of experience in leadership
positions in the corporate world as well as the start-up sector, including the United States,
Europe and Israel. Harel founded MEDX Ventures Group in 2010, a unique investment and
management firm, and serves as its CEO and Company Group Chairman.
Harel serves as the CEO, President & Chairman of Microbot Medical Inc. (NASDAQ:
MBOT), where he co-founded the company in 2011 and led it through its successful
listing on NASDAQ in 2016. He is also the founder and Chairman of XACT Robotics
Ltd., a promising early stage medical robotics venture, and the founder and Chairman of
MEDX Xelerator LP, a government supported medical devices incubator in Israel, with a
partnership between MEDX Ventures Group, Boston Scientific Corporation, Intellectual
Ventures and Sheba Medical Center. Until 2013, Harel served on the board of directors
at ConTIPI Ltd., and played an instrumental role in its commercial efforts, resulting in its
acquisition by Kimberly Clark Corporation in 2012.
Until 2010, Harel served as a Worldwide Group Marketing Director at Johnson &
Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic
marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson
(Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle
East and Africa. During his tenure, both companies enjoyed continuous growth in
revenues and new product launches (both from internal R&D and M&A). Prior to this,
Harel held several management positions in marketing and sales at Johnson & Johnson
A former professional basketball player, Harel played for numerous professional teams
in the Israeli and European leagues. Prior to turning professional, Harel played at Siena
College for the Siena Saints, an NCAA Division I Basketball Program.
Harel is a guest speaker for management and innovation courses at leading universities
in the United States and Israel, including the Technion - Israel Institute of Technology.
Harel holds a Bachelor of Science (BS) from Siena College (USA) and a Master in
Business Administration (MBA) from Manchester University (UK).
Harry Leider, MD, MBA has over 25 years experience as a physician executive in a variety
of innovative healthcare organizations. As Chief Medical Officer and a Group Vice
President of Walgreens, he is responsible for developing enterprise-wide health and wellness
services that provide customer value and improve patients’ lives. Prior to joining
Walgreens, Dr. Leider was Chief Medical Officer and Senior Vice President of Ameritox, a
national laboratory that provides medication monitoring services to physicians that treat
chronic pain and serious mental illness.
In addition to his extensive background in population health, Dr Leider has broad experience
in managed care. He served as Chief Medical Officer at XLHealth, a Population Health
company and Medicare Advantage plan that served seniors with chronic illnesses. Previously he was Chief
Medical Officer for HealthNet, a hospital-owned managed care organization, and a physician executive at
Harvard Pilgrim Health Plan.
Dr. Leider speaks frequently to national audiences and is a core faculty member for the American Association
of Physician Leadership, where he was a past-President and Board Chairman. He currently serves on the
Oliver Wyman Leadership Alliance, the Kennedy Forum Leadership Council, and the Boards of Mobile Help
and Tyto healthcare.
His publications appear in journals and books including: the Internet of Healthy Things, the Essentials of
Medical Management and Practicing Medicine in the 21 st Century. Dr. Leider is a founding board member of
the Disease Management Association of America and served on the Board of the Institute of Aging at the
University of Pennsylvania.
Dr. Leider obtained a BA from Pennsylvania State University, an MD from the University of Pennsylvania,
and his MBA from the University of Washington Foster School of Business. For six years he was an attending
physician at Brigham and Women’s Hospital and faculty member at Harvard Medical School.
Ilan Danieli has served as Precipio's CEO since founding the company in
2011. With over 20 years managing small and medium-size companies,
some of his previous experiences include COO of Osiris, a publicly-traded
company based in New York City with operations in the US, Canada,
Europe; and VP of Operation at Laurus Capital Management, a multi-billion
dollar hedge fund; as well as in various other entrepreneurial ventures. Ilan
holds an MBA from the Darden School at the University of Virginia, and a
BA in Economics from Bar-Ilan University in Israel, and served in the Israeli
military as a tank commander. He is also a private pilot, and while on the
ground, he enjoys travel, scuba diving, skiing (snow and water), and also
dabbles in gourmet cooking.
Imran Andrabi, MD, is president and chief executive officer of ThedaCare®, a community health system consisting of seven hospitals, 32 clinics and related services across nine counties in Northeast Wisconsin.
Dr. Andrabi joined ThedaCare in 2017 with extensive experience leading safe, quality healthcare in the Midwest. He is passionate about process improvement and providing world-class experiences and care for patients and the caregivers who serve them. He believes in team-based care and innovative design and delivery of this care. Dr. Andrabi characterizes himself as an entrepreneur and clinician who is always looking for next-generation solutions in healthcare delivery.
Dr. Andrabi is a family medicine physician who graduated from King Edward Medical College in Lahore, Pakistan. He completed his transitional year residency and then his family medicine training at Mercy Hospital in Toledo, Ohio, where he served as chief resident. He is board certified by the American Board of Family Medicine and American College of Managed Care Medicine and is a fellow of the American Academy of Family Physicians.
Before joining ThedaCare, Dr. Andrabi was chief operating officer and then president and CEO of Mercy Health in Toledo, Ohio.
He was integrally involved with physician partnerships; growing the clinically integrated network, accountable care organization and physician group; and creating access and business development opportunities in the region. He was instrumental in starting two free standing emergency departments in the region, developed a comprehensive cancer center in partnership with a large group of oncologists and radiation oncologists, and developed ambulatory centers
with diagnostic and therapeutic capabilities in the region.
In addition, while with the Mercy Health system, Dr. Andrabi served as chief operating officer of a 350-bed hospital, chief operating officer and then CEO of a 450-bed Level 1 trauma and regional referral center, president of the Mercy Physician Group and president of the Clinically Integrated Network, and chief network integration officer for the region in Toledo. He served as chairman of the board for Mercy Health Physicians across the Mercy Health system, with 1,200 physicians in Ohio and Kentucky, and vice chair of the board of the clinically integrated network Advanced Health Select in Ohio.
Dr. Andrabi has experience as a private practice physician.
Dr. Andrabi has served on the academic faculty in a family medicine residency program and as program director of a family medicine and transitional year residency training program. He has been on the faculty at the Medical College of Ohio and the Ohio University Heritage College of Osteopathic Medicine. He has received numerous teaching awards from the medical residents over the years. He has also served as a designated institutional official at Mercy Health-St. Vincent Medical Center, which sponsors 13 different residencies and fellowship programs.
Dr. Andrabi is married with three children: two grown sons and a daughter. He loves music, traveling, golf (when he can make it), good food and cars.
Jacob Chacko brings to Ignyta a broad range of experience with financing, managing, and advising companies in the life sciences field. At Ignyta, Dr. Chacko leads multiple functions including Finance, Accounting, Investor Relations, Communications, Facility Operations, and IT, and has helped lead nearly $500 million in capital raises. Dr. Chacko joined Ignyta in May 2014 from TPG Capital, a global private investment firm with approximately $70 billion of assets under management, where he served as Vice President focused primarily on healthcare and digital media since August 2008. At TPG, Dr. Chacko helped lead teams that successfully completed acquisitions having an aggregate value of over $10 billion. He served on the boards of directors of RentPath and EnvisionRx, was an advisor to the audit committee of Par Pharmaceutical, and was a board observer to IMS Health and Quintiles Transnational. Dr. Chacko previously served on the Board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford and is Chairperson of the Western Regional Selection Committee for the Marshall Scholarship. Prior to TPG, Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his M.B.A. with Distinction from Harvard Business School, and was president of his class at both institutions. Prior to this, Dr. Chacko was a consultant serving healthcare clients at McKinsey & Company, a management consulting firm. Dr. Chacko received a M.Sc. in economic and social history from Oxford University, where he was a Marshall Scholar, and a B.A. in biology, B.S. in gerontology, and minor in health policy and management from the University of Southern California, where he graduated as the University Valedictorian.
Jaime Wesolowski was appointed President and Chief Executive Officer of Methodist Healthcare System of San Antonio (Methodist) in 2007. Methodist is a unique partnership with equal ownership between Hospital Corporation of America (HCA – for profit) and Methodist Healthcare Ministries (MHM – not-for-profit). The System employs over 10,000 people in its 27 facilities, has 400 plus volunteers, and over 2,700 physicians hold clinical privileges at the nine Methodist Healthcare hospitals. Methodist has received numerous awards in recent years, including the Texas Hospital Association Bill Astor Award in 2012, the Texas Healthcare Quality Improvement Award in 2012, and the Texas Award for Performance Excellence in 2014, demonstrating the highest level of quality in the state of Texas. Jaime has led the organization in the use of the Malcom Baldrige Framework for Performance Excellence to ensure organizational sustainability, continuous improvement, and a focus on patient driven results. Methodist was recently named a 2016 Top Workplace by the San Antonio Express-News, and three of its hospitals made the list of Modern Healthcare’s “Top 150 Best Places To Work In Healthcare For 2017”.
Jaime earned his Master’s Degree in Healthcare Administration from Xavier University, and his Bachelor’s of Science from Indiana University in Healthcare Administration.
Before joining Methodist, Jaime served as the CEO of Riverside Community Hospital in Riverside, CA from 2003 to 2007. Prior to that, he was the CEO of Oak Hill Hospital in Spring Hill, FL for four years. He also spent ten years as the CEO of Meadowcrest Hospital in New Orleans, LA.
Jaime was inducted into the Studer Group Fire Starter Hall of Fame in 2011, was named the American Hospital Association (AHA) Grassroots Champion for the State of Texas in 2013, and was honored as a Healthcare Hero by the San Antonio Business Journal in October, 2016.
Jaime’s professional affiliations include memberships in the AHA and the Texas Hospital Association (THA) where he served on the Board from 2011-2016. Recently, he was appointed to serve on the Texas Health Improvement Network Advisory Council, a committee of the Office of Health Affairs, Population Health, of The University of Texas System. In addition, he also serves on the THA HOSPAC Board of Governors.
Being a cancer survivor himself, he is an avid supporter of the American Cancer Society and other cancer related organizations. He and his wife, Lori, co-chaired the 2010 American Cancer Society’s Cattle Baron’s Gala, and have remained active with ACS since then. In 2016, he and other Senior Leaders of Methodist, and their spouses, co-chaired the 2016 Cattle Baron’s Gala. Jaime believes his personal experience as a cancer survivor has given him more defined insight and compassion to the physical, emotional, and spiritual needs of patients and their families.
Jaime and Lori have been married for 27 years. They have two children, Ellie, age 21 and Grayson, age 20. His interests include golf, exercising, and a variety of community support activities.
Mr. Dentzer joined Curis as CEO in March 2016.
Chief Financial Officer, Dicerna Pharmaceuticals
Chief Financial Officer, Valeritas
Chief Financial Officer, Amicus Therapeutics
VP & Corporate Controller, Biogen
Various Positions at DuPont, Kemper Financial Services and Bank of America Merrill Lynch (formerly Bank of Boston)
MBA, University of Chicago, and BA, Boston College
Jan M. Lundberg, Executive Vice President, Science and Technology and President,
Lilly Research Laboratories (LRL), member of the Company’s Executive Committee.
Lundberg came to Lilly in January, 2010 with broad experience in academia, biotech
and big pharma. He joined as the leader of LRL, encompassing Research and the
Medicines Development Unit (R&D). Prior to joining Lilly he served for ten years as
Global head of research at AstraZeneca. He has broad disease biology, drug hunting
and drug development expertise across several therapeutic areas. This includes
disease area strategies, timely valued medicines and next generation development
strategies to enhance success rates and speed, technology platforms, as well as
synergizing internal capabilities with external partnering. He has a medical education
from University of Gothenburg and a Ph.D. from Karolinska Institute in Stockholm,
Sweden. He has received an honorary doctorate from University of Uppsala. Before
joining the biopharmaceutical company, Astra, as preclinical research head in 1996, he
was professor at the department of pharmacology, Karolinska Institute. Key impact
areas of his integrative and translational research covering nervous system, endocrine,
cardiovascular and respiratory areas research are: CGRP antagonists in migraine,
endothelin antagonists and nitric oxide for vascular indications and pancreatic
polypeptide family (NPY, PYY) for cardiometabolic applications. He has published more
than 500 scientific papers and has received several academic research awards in
addition to being a top 100 ISI highly cited scientist. He was one of the founders of the
Innovative Medicines Initiative (IMI) in Europe, the Accelerating Medicines Partnership
(AMP) in the U.S. being on the executive committee of AMP and of TransCelerate
Biopharma, Inc. He has VC experience from Aerocrine AB (co-founder), Medimmune
and Lilly ventures. He is currently on the boards for TransCelerate Biopharma, Inc.,
Pharma Foundation and BioCrossroads.
He has an interest in exercise, sports and outdoor activities.
Jason Michael O’Rourke is the Chief Executive Officer and Founder of Quotient Health.
Mr. O’Rourke’s vision of a world where Healthcare systems drive down the cost of healthcare and increase access to cutting-edge lifesaving care is what drives him in his passion for developing new tools for optimization and interoperability that until now has only been a distant possibility.
Quotient Health started as a brainchild years ago as Jason witnessed firsthand the inefficiencies of Healthcare Systems technical design and implementation of their Electronic Medical Records systems, and the complex workflows that supported them.
Once the limitations in computing power and software finally disappeared, Quotient Health under his direction began developing the sophisticated algorithms and methods of delivery that had once only been a theory.
Throughout the years Jason has become a thought leader in the Optimization and Future of EMR delivery, managing projects and optimizing systems at Cleveland Clinic, UCLA, Providence H&S, Sutter Health, Unv. of Chicago Medical and Mayo Clinic (among others).
Mr. O’Rourke was a featured keynote speaker at the first Security Design Forum held by Epic Systems (a leading vendor in EMR) in 2010 and since helped to author the current implementation playbook followed by Epic customers, as well as authoring numerous white papers on EMR Design and Governance within a HIPPA complainant environment.
Jason Michael O’Rourke graduated with honors from the United States Air Force School of Applied Cryptologic Science in 2001 after being selected for a unique program while enlisted in the United States Marine Corps. He was awarded a Commanders Award for academic excellence and awarded multiple service medals for his support of Operation Noble Eagle Serving Honorably in Joint Operations Command Operations within the DoD, in a Defensive Counter Intelligence role developing multidimensional data analytics processes.
Mr. O’Rourke’s hands-on philanthropy and care for the wellbeing of others was at the forefront when he spent nearly a year in Cambodia helping to assist NGOs in the delivery of rice overland to villages cut off by drought-ridden waterways, often navigating non-existent roads in the most densely land-mined area of the world.
When Mr. O’Rourke has free time, he enjoys overseas travel, immersing himself in new cultures and countries, fine dining and the arts.
Jay Campbell, Vice President, Business Development and Investor Relations,
Mr. Campbell joined Immutep in February 2017. He was previously Senior
Director of Business Development and Investor Relations at Kolltan
Pharmaceuticals, Inc., a privately-held biotechnology company developing
biologic therapeutics targeting receptor tyrosine kinases for oncology and
immunology, which was acquired by Celldex Therapeutics, Inc. in December
Prior to Kolltan, Mr. Campbell spent over 13 years working in the financial
services industry and as an independent business development consultant,
the majority of which was as an investment banker focusing on the life
sciences industry. During this time, Mr Campbell was a business development
consultant to ISTA Pharmaceuticals, Inc. in connection with the company’s
review of strategic alternatives that culminated in the sale of the company to
Bausch & Lomb in 2012.
Mr. Campbell previously worked at Maxim Group, Royal Bank of Scotland,
ABN AMRO, Rothschild, and Schroders. Throughout his career, he has
worked on over 25 successful financing, licensing, and M&A transactions
representing more than $13.0 billion. Jay serves as a member of the board of
directors of Update Pharma, Inc., a privately held clinical-stage small molecule
company focused on developing overlooked or underutilized anti-cancer
drugs. He received a BSBA in Management from Bucknell University and
minored in Spanish.
Jeffrey D. Abbey has served as our President and Chief Executive Officer and a
member of our board of directors since February 2010. Mr. Abbey served in
various other positions at our company from September 2002 to February 2010,
including as our Vice President of Business Development from February 2004 to
January 2009 and as our Chief Business Officer from January 2009 to February
2010. Prior to joining us, Mr. Abbey served as Vice President of Business
Development and Finance at Internet Appliance Network, an information
technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg
and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an
A.B. in mathematical economics from Brown University and an M.B.A. and J.D.
from the University of Virginia.
Jeffrey Wolf is the founder and CEO of Heat Biologics. He was formerly the founder and managing director at Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon novel research breakthroughs.
Throughout his career Mr. Wolf has created life science startup companies and actively supported the growth of these companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and Chairman) which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases and GenerationOne (founder and CEO), focused on mobile-based healthcare solutions.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.
James E. Shmerling was named President and Chief Executive Officer at Connecticut Childrens Medical Center on October 1, 2015. For over three decades, Dr. Shmerling has served in management roles in childrens hospitals and is nationally recognized as a leader in issues concerning childrens health and wellness. Prior to joining Connecticut Childrens, Dr. Shmerling spent the last eight years as the Chief Executive Officer of Childrens Hospital Colorado, one of the top ranked childrens hospitals in the nation. Before that, he was the Executive Director and Chief Executive Officer of the Monroe Carell Jr. Childrens Hospital at Vanderbilt from 2002 to 2007. He was the Senior Vice President of Methodist Healthcare and President of Le Bonheur Childrens Medical Center from 1995 to 2002, and was Le Bonheurs Chief Operating Officer from 1991 to 1995. He served as the Associate Director of Hospitals at Indiana University Hospitals and Administrator of the James Whitcomb Riley Hospital for Children from 1987 to 1991. Dr. Shmerlings career in childrens hospitals began in the Childrens Hospital of Alabama where he progressed in administrative responsibilities from 1979 to1987, the last of which was as its Associate Administrator. He earned his Bachelor of Science Degree in Health Education from the University of Tennessee in 1976. In 1980, he was awarded a Master of Science Degree in Hospital and Health Administration from the University of Alabama at Birmingham. He earned a Master of Business Administration from Samford University in 1984 and his Doctorate of Health Administration from the Medical University of South Carolina in 1999. Dr. Shmerling is a Fellow in the American College of Health Care Executives (ACHE). He is an adjunct faculty member in the Hospital Administration programs, University of Alabama at Birmingham. Additionally, Dr. Shmerling is active in several national healthcare organizations. Currently he serves as: Board member of the Childrens Hospital Group, Dublin, Ireland Immediate Past Chair of the Board of Childrens Miracle Network Hospitals, Salt Lake City, Utah Immediate Past Chair of the Board of Childrens Hospital Association, Alexandria, VA Chair of the Child Health Patient Safety Organization, Inc., Overland Park, KS, a component entity of the Childrens Hospital Association Chair Elect on the Governing Council of the American Hospital Associations Section for Maternal and Child Health, Washington, D.C. Past Board Chair of the Colorado Regional Health Information Organization (CORHIO), Denver, Colorado Dr. Shmerling is a native of Nashville, Tennessee.
José Baselga is the Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK) and
Professor of Medicine at Weill Cornell Medical College. His long standing research interests are
in the development of targeted agents for the treatment of breast cancer and in studying
strategies to overcome mechanisms of resistance, with over 457 peer-reviewed publications to
date. He conducted pivotal laboratory and clinical studies that led to the approval of
trastuzumab, pertuzumab and everolimus, among other therapies. His current work is in
targeting PI3K and deciphering mechanisms of resistance to anti-estrogen therapies. Prior to
MSK, Dr. Baselga was the Chief of the Division of Hematology / Oncology, Associate Director of
the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard
Medical School. He was also the Chairman of Medical Oncology and Founding Director of the
Vall d’Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga is a past President of the
American Association of Cancer Research (AACR), a past President of the European Society
for Medical Oncology, and a past member of the Board of Directors for the American Society of
Clinical Oncology. He is an elected member of the National Academy of Medicine, the
American Society of Clinical Investigation, the Association of American Physicians, and a Fellow
of the AACR Academy. He is a past member of the Editorial Boards of Cancer Cell, Journal of
Clinical Oncology, and Clinical Cancer Research and is the founding editor-in-chief for the
AACR flagship journal Cancer Discovery.
Kenneth Garay, M.D., FACS, serves as the Chief Medical Officer (CMO) and Senior Vice President of the Jersey City Medical Center (JCMC). JCMC is a RWJBarnabas Health facility and part of the largest hospital system in the state. He assumed his position in 2008 and under his leadership the Jersey City Medical Center has attracted over 388 new physicians to its Medical-Dental staff. He has worked diligently to improve the physician experience and support the hospital's mission of “Enhancing Life”.
JCMC serves as the regional state-designated regional trauma center, comprehensive cardiac center, neonatal intensive care center (NICU) and provides Advanced Life Support (ALS) for the Hudson County Region. Hudson County is across the Hudson River from New York City and one of the most densely populated and diverse counties in the United States. JCMC is a not for profit hospital in its region sounded by for profit and out of network hospitals.
The Jersey City Medical Center is the first and only hospital in Hudson, Union or Essex counties to receive – and be recertified for – Magnet-award status for nursing excellence. The hospital’s Emergency Medical Service (JCMC EMS) was the first of its kind in the U.S. to earn triple accreditation in dispatch, education and emergency medical service. The hospital has received an “A” Hospital Safety Score from The Leapfrog Group, an independent national nonprofit group measuring hospital safety and quality, for the 9th consecutive time (one of only 153 hospitals nationally to achieve this). During the past twelve months Dr. Garay was instrumental in the hospital achieving the Vision of Performance Award (VOPE) and is a key leader on the trail toward the national Baldrige Award. In July the hospital became ISO 9001-2008 certified in organizational processes.
Working closely with Joseph Scott, FACHE, President and CEO of Jersey City Medical Center, Dr. Garay helped develop the four pillars under which Jersey City Medical Center operates: Patient Safety, Clinical Quality, Satisfaction, and Economic Health. During his tenure as CMO, Jersey City Medical Center also opened the Cristie Kerr Women’s Health Center; a Downtown Women’s Health Center; a Cardiac Diagnostic Center, a Spine and Orthopedic Institute, and an Ambulatory Surgery Center which is a joint venture with local physicians.
He has been listed in the New York – New Jersey Region as a “Top Doctor” for nine consecutive times by Castle Connelly. Local organizations have recognized Dr. Garay for his leadership and community service including the Boy Scouts of America who presented him with the 2015 “Good Scout Award”. In 2015, he was named “Jersey City Police Surgeon”.
Dr. Garay was interviewed by a number of news organizations, including NJN News, to elaborate on how the hospital accomplished a change from “worst to first” in such a short period of time. Dr. Garay has also been recognized individually in multiple Castle Connelly surveys as a “Top Doctor” in the field of Otolaryngology by a survey of his peers.
Dr. Garay is board certified by the American Board of Otolaryngology and is a graduate of Columbia College in New York City and Temple University School of Medicine. He completed his surgery residency at Abington Memorial Hospital and his residency at Columbia Presbyterian Medical Center in New York. From 1982 to 1992, Dr. Garay served as an instructor of Clinical Otolaryngology and a visiting lecturer at Columbia University College of Physicians and Surgeons, where he instructed both ENT's and surgeons in anatomy and surgical technique.
Dr. Garay is the author of numerous articles and publications and is the founder and senior partner of the Head and Neck Surgical Associates and the Center for Sinus and Nasal Disease.
Despite his busy professional career, Dr. Garay occasionally finds time for a well-deserved round of golf or to travel to interesting designations around the world.
Kevin B. Churchwell, MD, is the Executive Vice President of Health Affairs and Chief Operating Officer at Boston Childrens Hospital. He provides leadership, direction, integration and oversight for the medical delivery system, while partnering with the Chief Executive Officer on a full range of research, clinical, academic, operational and strategic issues. Prior to joining Boston Childrens Dr. Churchwell was Chief Executive Officer for Nemours/Alfred I. duPont Hospital for Children in Wilmington, DE. As the lead administrator in the Delaware Valley, Dr. Churchwell was actively driving efforts to increase the quality and affordability of care for all children. Under his leadership, the Leapfrog Group recognized Nemours duPont as one of 12 safest childrens hospitals. Dr. Churchwell also served as the CEO and Executive Director for the Monroe Carell Jr. Children's Hospital, part of the Vanderbilt University Medical Center in Nashville, TN. He previously served in several other capacities, including Chief-of-Staff, Medical Director for the Children's Health and Injury Prevention Program, Medical Director for the Pediatric Critical Care Services, and Transport Director. A graduate of Massachusetts Institute of Technology and Vanderbilt Medical School in Nashville, Dr. Churchwell completed his pediatric residency and a clinical fellowship in Anesthesia and Pediatric Critical Care at Boston Children's Hospital. Since 1993, Dr. Churchwell has been a clinician and faculty member at Vanderbilt University Medical Center. He is a diplomat for the National Board of Medical Examiners and is board certified with the American Board of Pediatrics. Dr. Churchwell was recently appointed the Robert and Dana Smith Associate Professor of Anesthesia at the Harvard Medical School.
Kurt Newman, MD, President and Chief Executive Officer, is a surgeon and recognized leader in pediatric health, nationally and in Washington, DC.
Since becoming CEO in 2011, he has fostered a culture of patient-centered care and championed innovations in research, operations, and clinical care. He has forged productive partnerships with other health systems in the region, with government and community entities and with industry at the local, national, and global level. He is also a strong advocate for expanding mental health access for kids and has led two national forums on this issue.
Dr. Newman joined Children’s National as a surgical fellow in 1984 and became Surgeon-In-Chief and Senior Vice President for the Joseph E. Robert, Jr. Center for Surgical Care in 2003. He was instrumental in developing the vision for the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National, inspired by the bold vision of making surgery for children minimally invasive and pain free. When the Institute was created in 2009 through a transformational $150 Million gift, Dr. Newman served as its Founding Vice President.
Currently, Dr. Newman serves as the Chair of the Children’s Hospital Association Leadership Committee on Advocacy and Policy and as a member of the Board of Trustees. He is also a member of the Board of Directors for the District of Columbia Hospital Association and a member of the Commonwealth Council on Childhood Success in Virginia. In addition, Dr. Newman serves on the Board of the Economic Club of Washington, Greater Washington Board of Trade, Federal City Council, DC Chamber of Commerce, and Fight for Children. Previously, he served as a Board Member of Commissioners of The Joint Commission, a member of the Board of Governors of the American Pediatric Surgical Association, and as Chair of the Surgery Section of the American Academy of Pediatrics.
Dr. Newman is a Professor of Surgery and Pediatrics at the George Washington University School of Medicine and Public Health. He is a graduate of the University of North Carolina at Chapel Hill and received his medical education at Duke University. He completed his surgical residency at the Brigham and Women's Hospital and also served as the Arthur Tracy Cabot Fellow at Harvard Medical School.
In 2017, Dr. Newman’s medical memoir Healing Children: A Surgeon’s Stories from the Frontiers of Pediatric Medicine, debuted as an Amazon Best-Seller in Pediatrics and earned national attention and critical praise in The New York Times Book Review, The Washington Post, and Harvard Business Review.
Dr. Lan Huang is Co-founder, Chairman and CEO of BeyondSpring. Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry and invented and holds patents for a number of biotech products for oncology and dermatology indications. In 2009, she was the recipient of China’s “Thousand Talent Innovator Award.”
Prior to founding BeyondSpring, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., whose self-designed cancer peptide drug’s China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International, a clinical CRO company in China, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies.
Dr. Huang was trained at Memorial Sloan Kettering Cancer Center, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science. The immense importance of this field is illustrated by the 2004 award of the Nobel Prize in chemistry to the founders of ubiquitin-mediated protein degradation. She received her Ph.D. in chemistry in four-and-a-half years from the University of California at Berkeley, where she won the graduating Ph.D. woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers.
Dr. Kaiser is the leading health sciences executive at Temple University in Philadelphia, PA. He
serves as president and chief executive officer of the Temple University Health System, senior
executive vice-president of Health Affairs, and the Lewis Katz Dean of the Lewis Katz School of
Medicine at Temple University. Prior to joining Temple University, Dr. Kaiser served as
president of the University of Texas Health Science Center at Houston, one of six health-related
campuses of the University of Texas. He graduated from Tulane University School of Medicine
in 1977 and completed his residency in general surgery as well as a fellowship in surgical
oncology at the University of California, Los Angeles. He then completed a residency in
cardiovascular and thoracic surgery at the University of Toronto. Following that, he held
positions as thoracic surgeon at Memorial Sloan-Kettering Cancer Center and assistant professor
of surgery at Cornell University Medical College (New York) and as associate professor at the
Washington University School of Medicine (St. Louis). At the University of Pennsylvania, Dr.
Kaiser held a variety of positions, including chief of general thoracic surgery, founder and
director of the university’s lung transplantation program, and director of its Center for Lung
Cancers and Related Disorders. In 1996, he was named the Eldridge Eliason Professor of
Surgery and, in 2001, was named the John Rhea Barton Professor and chair of the department of
surgery as well as Surgeon in Chief for the University of Pennsylvania Health System.
Dr. Kaiser’s clinical interests include lung cancer, malignant mesothelioma, and mediastinal
tumors. He is the author or co-author of 16 books and more than 300 original papers, and he
serves on multiple editorial boards. Dr. Kaiser has served in a number of leadership capacities
for professional societies and associations and has been a director of the American Board of
Surgery and the American Board of Thoracic Surgery. In 2005, he was elected to the National
Academy of Medicine.
Laura joined Flagship Pioneering in 2016 after working at Flagship portfolio companies Epiva and Evelo, where she was director of scientific affairs. While at Epiva, Laura conceived and led the company’s programs in autoimmunity and food allergy. She subsequently played a critical role in the merger between Epiva and Evelo, which produced the leading immuno-microbiome company. Laura has been involved in a range of projects at VentureLabs across therapeutics, diagnostics and agriculture.
Laura previously completed her post-doctoral fellowship in neurobiology at Harvard Medical School, where she studied the molecular mechanisms underlying circadian rhythms and served as an instructor in neurobiology. She founded Harvard Medical School’s Critical Discussion Group, an interdisciplinary, scientific innovation and invention group, and catalyzed its replication at numerous leading academic institutions, including Stanford and Columbia.
Laura is the author of more than 10 peer-reviewed publications and an inventor on 11 patents and applications. She also holds a Ph.D. in epigenetics and molecular biology from the Hebrew University of Jerusalem Medical School, where she studied mechanisms of long-term gene expression in mammalian cells.
Founder and CEO at ReviveMed, experienced engineer and entrepreneur with a Ph.D. in Biological Engineering from MIT.
During her PhD at MIT, Dr. Pirhaji developed a pioneering machine-learning technology, which translates data from small molecules or metabolites into therapeutic solutions and was published in Nature Methods. Dr. Pirhaji founded ReviveMed Startup Company to commercializes this technology, and enable developing the right therapeutics for the right patients by leveraging machine-learning and metabolomics.
Lester P. Schindel, FACHE, is Executive Vice President and Chief of Provider Services for Visiting Nurse Service of New York (VNSNY). In this role, Mr. Schindel oversees the organization’s CHHA (Certified Home Health Agency), Hospice and Palliative Care, and private pay division Partners in Care, as well as the work of the VNSNY Center for Home Care Policy and Research. He is responsible for ensuring that the care delivered by VNSNY meets the highest standards of quality, patient satisfaction and safety, operational efficiency, and cost effectiveness. Founded in 1893, VNSNY is the largest not-for-profit home- and community-based health care organization in the United States, serving the five boroughs of New York City and Nassau, Suffolk and Westchester Counties. On any given day, VNSNY has more than 30,500 patients in its care.
Mr. Schindel has more than three decades of executive-level experience in the for-profit and not-for-profit healthcare sectors. He has been recognized as a leader in the post-acute care sphere, with expertise in operational transformation; strategic business planning and growth; physician recruitment and integration; quality performance; development of new models of care delivery and payment, including Accountable Care Organizations; integration of regional acute care hospitals and physician networks; and building and maintaining successful medical staff relationships.
In his prior role as President and CEO of the New England Sinai Hospital, New England’s leading post-acute care facility, Mr. Schindel introduced a pulmonary and medical inpatient satellite unit at Caritas Carney Hospital; a sleep medicine/sleep disorders program; a simulated living center to enhance rehabilitation therapies; and a wound center and hyperbaric oxygen therapy program.
Immediately before joining VNSNY, Mr. Schindel worked for Prospect Medical Holdings, where he was CEO at the 357-bed Waterbury Hospital, as well as the Prospect New England Region Chief Strategy, Growth and Development Officer. In this combined role, he advised CEOs of the five hospitals of the Northeast Region on strategy and growth, including the implementation of Prospect‘s risk-based, integrated delivery model of care to bring population health and value-based contracting strategy to each market. Mr. Schindel has also served as CEO and President of Charter Care Health Partners in Providence, RI. It is comprised of Roger Williams Medical Center and Our Lady of Fatima Hospital, Elmhurst Extended Care facility and CCHP Physician group and CCHP VNA. He worked for Steward Healthcare, the largest privately held heath care company in the U.S., as CEO of its northeast division at the 472-bed Holy Family Hospitals in Methuen and Haverhill, MA. Prior to joining Steward, he was President of the 122-bed Merrimack Valley Hospital in Haverhill, MA, and the 209-bed New England Sinai Hospital in Stoughton, MA, the premier post-acute care facility in Massachusetts.
Mr. Schindel is a Fellow in The American College of Healthcare Executives. He has been a national speaker on the integrated delivery network development. One of his areas of focus has been the strategies necessary to facilitate positive working relationships for physicians, hospitals and other healthcare entities to work effectively together to manage the delivery of care in a value-based purchasing environment. During his time as CEO and President of New England Sinai, he was very active in working with CMS, Federal and State legislators, and the National Association of Long Term Hospitals (NALTH) on public policy issues involved in the delivery of care to the chronically ill, rehabilitation and the delivery of post-acute care.
Mr. Schindel has served on the Boards of Directors of numerous organizations, among them the Hospital Association of Rhode Island and the Massachusetts Hospital Association, where he was also Chairman of the Association's Post-Acute Care Specialty Hospital Chief Executive Officer Forum. He was honored twice as Grassroots Champion by the American Hospital Association (AHA) for his work in Massachusetts and Rhode Island in 2009, and 2016 for his legislative and community advocacy work on public policy issues. He has served as the President and Chairman of the Board of Metrowest Jewish Family Services, an organization dedicated to assisting families, the elderly and Immigrants in the greater Boston area to live useful and productive lives. He has also served on the Board of Northern Essex Community College (NECC); the Rhode Island Governor’s Healthcare Delivery Task Force; various Chamber of Commerce Boards in Providence, Rhode Island; and the Merrimack Valley, Haverhill, Metro South and Neponset Valley Chambers of Commerce in Massachusetts. In addition, he has been actively involved in youth sports, serving as President and Board Member of the Framingham United Soccer Club and Division Director of TBA Youth Basketball.
Dr. Aklog is an adult cardiac surgeon/entrepreneur and Chairman & CEO of PAVmed Inc. (Nasdaq: PAVM), a
multi‐product medical device company which he co‐founded based in 2014 on a portfolio of five of his own
inventions. He previously co‐founded Pavilion Holdings Group LLC which created four medical device
companies including Vortex Medical, based on his invention AngioVac® and was sold in 2012 to
Angiodynamics (Nasdaq: ANGO) for $55 million. He practiced academic cardiac surgery for 15 years, with a
focus on innovation & medical technologies, serving on advisory boards for major medical device companies
Dr. Aklog received his AB from Harvard College, graduating Phi Beta Kappa and magna cum laude in Physics
and his MD, cum laude, from Harvard Medical School. He completed his general and cardiothoracic surgical
training along with a laboratory research fellowship at Harvard’s Brigham and Women’s Hospital and at
Boston Children’s Hospital, serving as Chief Resident in Cardiac Surgery at both institutions. He was awarded a
traveling fellowship by the American Association of Thoracic Surgery to receive advanced training in heart
valve surgery under Sir Magdi Yacoub of Harefield Hospital, London and Professor Alain Carpentier of L’Hôpital
Dr. Aklog joined the Harvard faculty and Brigham and Women’s Hospital as an Assistant Professor of Surgery in
1999. In 2002 he moved to Mount Sinai Medical Center in New York City where he served as Associate Chief
of Cardiac Surgery, Assistant Professor of Surgery, Director of Minimally Invasive Cardiac Surgery and
Associate Thoracic Surgery Residency Program Director. In 2006, he was recruited to Phoenix, Arizona to
serve as Chair of the Cardiovascular Center and Chief of Cardiovascular Surgery at St. Joseph’s Hospital and
Medical Center’s Heart and Lung Institute where he initiated one of the first patient focused‐disease centered
Valve and Atrial Fibrillation Clinics in the country and a regional mitral valve repair Center of Excellence and
During his academic and clinical career, Dr. Aklog was active in innovative approaches to heart surgery —
including mitral valve repair, off‐pump bypass surgery using arterial grafts, minimally‐invasive and robotic
surgery and pulmonary embolectomy. He has published 38 peer‐reviewed articles and 10 book chapters, and
has been invited to lecture and operate throughout the world. He has held leadership positions in national
and international organizations, including the Board of Directors of the International Society of Minimally
Invasive Cardiac Surgery and on several governmental committees, including a Medicare Coverage Advisory
Throughout his career Dr. Aklog has been deeply involved in medical device innovation, serving on the
advisory boards of many leading medical device companies and startups. This led to his evolution into an
entrepreneur as a founding partner of Pavilion Holdings Group (PHG). PHG’s first company, Vortex Medical,
was sold Angiodynamics in 2012. Dr. Aklog invented its AngioVac® system and served as its Chairman and
Chief Technology Officer. He has 13 issued patents and several dozen pending patent applications. In 2014,
Dr. Aklog co‐founded PAVmed Inc. and has served as Chairman and CEO since its inception. PAVmed was built
on a proven business model, honed at the PHG companies, focusing on capital efficiency and speed to market.
He is also the lead inventor on most of PAVmed’s diversified pipeline of products which encompass a broad
spectrum of clinical areas including carpal tunnel syndrome, medical infusions, interventional radiology and
pediatric ENT. PAVmed went public on Nasdaq in 2016 and has a series of lead products moving towards
commercialization including the much‐anticipated CarpXTM device, a minimally invasive device that seeks to
revolutionize the treatment of carpal tunnel syndrome.
Lois Cormack is the President and Chief Executive Officer of Sienna Senior Living (TSX; SIA), a leading Canadian seniors’ living provider with 71 residences in key markets in Ontario and British Columbia. Sienna’s more than 11,000 employees are passionate about helping residents live fully, every day.
Since joining the company in 2013, Lois has led the organization through significant growth and transformation, more than doubling the size of the company and leading a successful rebranding and repositioning as a high quality provider. Her previous roles include President of Specialty Care, owner of an independent consulting practice and other senior leadership roles in the health care and seniors’ living sectors.
Lois is a respected leader in seniors’ living in Canada who is actively involved with organizations to advocate for sound policy on seniors’ care and services, previously chair of the Ontario Long Term Care Association. She actively supports a number of not-for-profits and charities that support seniors and youth, and currently serves on the Board of Governors at Seneca College.
In 2014 and 2015, Lois was named as one of Canada’s top female entrepreneurs in Profit/Canadian Businesses W100 in recognition for outstanding company growth and performance.
Lois holds a Masters of Health Administration from the University of Toronto and is a graduate of the Ivey Executive Program at University of Western Ontario.
Mark L. Wagar, is President of Heritage Medical Systems, an affiliate of the Heritage Provider Network serving over 1 million patient/members in integrated, population based health quality payment programs through medical groups and independent practice associations (IPA’s) in California, New York, and Arizona. He previously served as the President and CEO of Empire BlueCross BlueShield based in New York City and is an Operating Partner with Enhanced Equity Funds which invests exclusively in healthcare services organizations.
Heritage Provider Network (HPN), founded by Dr. Richard Merkin in 1979, is one of the nation’s leading physician-led healthcare solutions organizations. HPN manages one of the largest and most successful Pioneer ACO’s in the United States.
At Empire BlueCross BlueShield, Mr. Wagar led New York’s largest health insurer covering nearly 6 million people, and was a Senior Vice President in WellPoint, Inc. In both Heritage and at Empire, he has been engaged in an active leadership role in public policy, provider collaboration, and community engagement. During his tenure, Empire achieved net growth of over 1 million medical members, market leading member satisfaction results, and the introduction of the first major medical home network in metropolitan New York.
An experienced officer and director in public and private corporations, Mr. Wagar currently serves on the Boards of The New York Academy of Medicine, WhiteGlove, Inc, TurningPoint, and the Tannenbaum Center for Interreligious Understanding. He has been recognized as a Distinguished Alumnus of The Ohio State University, and a recipient of the Dr. Jonas Salk Memorial Mentor in Medicine Award, as well as an honoree helping fund numerous charitable causes supporting healthy communities and diversity. In 1971 he was a member of the Big Ten Champion basketball team of The Ohio State University.
Martha Schram is the President of Aegis Therapies, a position she has held since 2004. Ms. Schram is responsible for the overall leadership and direction of Aegis, including the management of the contract rehabilitation and wellness services Aegis provides to healthcare organizations and the oversight of Aegis growing home health, outpatient and wellness business. Aegis clients include skilled nursing facilities, assisted living facilities, independent living facilities, continuing care retirement communities, home care organizations and individuals utilizing Aegis Medically Oriented Gyms and outpatient rehabilitation services. Prior to becoming President of Aegis, Ms. Schram was a Division Vice President and Group Vice President for Aegis. Her varied and successful career prior to Aegis includes serving as an Area Vice President for NovaCare in Wisconsin; an Executive Director of Rehabilitation Services for Divine Savior Healthcare in Portage, Wisconsin; and Clinical Coordinator for the Veterans Affairs Medical Center in Madison, Wisconsin. Earlier in her career, Ms. Schram held a variety of senior management and leadership positions with increasing responsibility in geriatric healthcare businesses. Ms. Schram earned a Bachelor of Science Degree in Physical Therapy from the University of Colorado at Boulder. She serves on the Board of Directors of the National Association for the Support of Long-Term Care (NASL), and is Chairman of the NASL Medical Services Committee. She is also a member of The University of Colorado Physical Therapy Scholarship Endowment Board and the International Council on Active Aging Advisory Board.
Matthew is fortunately/unfortunately highly "Google-able" so you may know him as a concert pianist, composer, public speaker, and veteran of the agency world who survived a diagnosis of terminal brain cancer at the age 21 in 1996. Or you may know him as a bald, fedora-wearing healthcare disruptor, Founder/CEO of Stupid Cancer, and Chief Angry Officer of the young adult cancer movement. (Or neither. Or both.)
Newsweek branded him a "Cancer Rebel" for a 2017 cover story and The New York Times showed the world that his tiny, quirky office in TriBeCa has a several vintage Macs on his shelves (that still boot up) along with an upright piano, some original Transformers, and a 1983 Voltron.
Matthew's industry tirades can be enjoyed on US News and World Report, PM360, Huffington Post, and LinkedIn. He serves as strategic council to the Society for Adolescent and Young Adult Oncology, the Oncofertility Consortium, PCORI, Walgreens, and a whole bunch of Pharma and CRO companies.
Matthew has a BA in Music, Computer Science, and Sociology from Binghamton University. He lives in Brooklyn with his wife and miracle twins, Koby and Hannah.
Matt Murphy is currently President and CEO at Griswold International LLC, one of the nation's oldest non-medical home care franchise brands. Griswold operates over 200 locations in 32 states, and has both owned and franchised locations. Prior to joining Griswold, Matt was CEO of Financial Health Services, LLC, a third party billing and revenue cycle management business that services the senior care market. Between both businesses, Matt has dedicated the last 5 years to supporting passionate business owners who are committed to helping aging and disabled adults live independently. Prior to joining FHS, Matt spent 7 years with RecruitMilitary, a company specializing in helping veterans and their spouses connect with employers, and worked on everything from business development, to leading the sales force, to the role of Chief Operating Officer. During that time the company more than doubled in employees, while revenues and net income grew by double digits every year. Before that, he served as Vice President and Chief Operating Officer at Acquisition Management Services, Inc., a company that helped companies grow by acquisition. Prior to joining AMS, Matt was an in-house attorney for the University of Pennsylvania Health System, where he supported the systems network development and corporate growth activities. During the period between his undergraduate and legal studies, Matt was a Surface Warfare Officer in the United States Navy. While in the Navy, Matt served on the USS Hepburn (FF-1055) as the Gunnery Officer, Command Information Center Officer, and ultimately as Navigator. Matt holds a Bachelor of Science degree in Applied Science and Technology from Rochester Institute of Technology, and a Juris Doctorate from the State University of New York at Buffalo.
Matthew L. Plaud is an accomplished executive with over twenty years of experience in a highly regulated environment. Currently he is the CEO of SOTIO, LLC, the North American arm of the SOTIO Group. In his three years with SOTIO, he has risen through the ranks from starting as the Director of Apheresis Network Management, to taking on all aspects of Logistics, to ultimately being promoted to the CEO of the US operation. In his time in this role he has improved staff moral while enacting major savings programs.
Before joining SOTIO, Matthew held a series of progressively responsible roles within the American Red Cross. Starting as a laboratory technician, he spent over 17 years working in different areas of the organization until ultimately completing as the interim CEO of the Massachusetts Region.
Although his career was initiated in the laboratory, Matthew has spent his time expanding his knowledge of business and management. He is a graduate of UMass with a degree in Human Resource Management (Summa Cum Laude) and then went on to Eastern Nazarene College to earn a Master’s of Science in Management. He is passionate about his work and enjoys mentoring up-and-coming staff.
Michael Castagna is our Chief Executive Officer and serves on the Board of Directors for MannKind Corporation. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington.
Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.
Mr. Kidron serves as Chief Executive Officer & President of Oramed Pharmaceuticals, which he founded in 2006. Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.
Nadav co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI (Israeli Advanced Technology Industries) board; and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas (www.israel-innovation.com).
He holds a Bachelor’s degree in law and an international Masters in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.
Professor Riedemann is co-founder of InflaRx and has served as Chief Executive Officer since
inception of the company in 2007. Under his leadership, InflaRx was funded by international
investors in 4 financing series and the company successfully conducted its initial public offering at the
US Nasdaq stock exchange in November 2017. Throughout the company history, Prof. Riedemann
has served simultaneously as CFO as well as CMO of InflaRx and he was and continues to be critically
involved in the scientific developments of InflaRx leading anti-human complement C5a antibody
technology. He received his medical training at the Albert-Ludwig University in Freiburg, Germany
and Stanford University in the United States and graduated from Albert-Ludwig University in 1998.
He spent several years in basic science at the University of Michigan in the field of complement
immunology and inflammation before completing his board certification as General Surgeon at the
Hannover Medical School in 2007 where he still holds an adjunct Professorship for Experimental
Surgery. He is specialized as Intensive Care Physician and was the Vice Director of Intensive Care
Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He has served as
member of the Scientific Advisory Board and the Board of Directors of two large scientific
governmental funded research programs in Germany from 2012-2015. His research has been
awarded with several national and international awards and he published over 50 original research
articles in high ranked scientific journals.
Dr. Norvell Vandervall (Van) Coots is the President and CEO of Holy Cross Health and the President and CEO of the Maryland Region of Trinity Health.
Prior to joining Holy Cross Health in 2016, Dr. Coots retired from the Army as a Brigadier General, his final assignment was as Commanding General, Regional Health Command Europe, and as the Command Surgeon for the US Army Europe and 7th Army, with his headquarters located in Sembach, Germany. Previous assignments included Deputy Commanding General (Support), US Army Medical Command, and as the Assistant Surgeon General (Force Projection) of the Army, 2013-2014. From 2012-2013, Dr. Coots was deployed to combat as the Surgeon General, US Forces Afghanistan and Medical Advisor to the Commander of the International Security and Assistance Force Joint Command (NATO). From 2008- 2011, he served as the final Commander of the Walter Reed Healthcare System and Walter Reed Army Medical Center, in Washington, D.C.
Dr. Coots is a graduate of the University of Oklahoma College of Medicine. Board-certified in Dermatology, he has a Masters degree in Strategy from the Army War College. He has served around the world and has commanded at all levels, including company, clinic, hospital and medical center. Dr. Coots has received numerous awards and decorations that include the Distinguished Service Medal and the Defense Superior Service Medal. He has been awarded the Legion of Honor from France and is a member of the Order of Military Medical Merit. He has numerous civilian healthcare awards that include the Scroll of Merit of the National Medical Association. He is a member of the Alpha Phi Alpha and Sigma Pi Phi Fraternities, and is a member of the American Academy of Dermatology's Leadership Circle on Volunteerism.
Dr. Orsula Voltis Knowlton is Co-founder, President and Chief Marketing/New Business Development
Officer of Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC). TRHC is a healthcare technology
company optimizing medication safety by deploying new medication risk mitigation digital software
solutions and novel, proprietary medication decision support Medication risk management is TRHC’s
lead offering, and its cloud-based software applications, including EireneRx® and MedWise Advisor®,
provide solutions for a range of payers, providers and other healthcare organizations
Since the Company’s founding in 2009 and the welcoming of its first clients in 2011, Dr. Knowlton and
the TRHC team now serve 20-25% of the PACE market participants (Program for All-inclusive Care of
the Elderly) and provide interventions for high-risk individuals in Part D plans representing
approximately 15% of the total number of Medicare lives. The company has received numerous awards
including 2016 SmartCEO Culture Award and 2018 Top Workplaces by Philadelphia Media Network,
publisher of The Philadelphia Inquirer, Daily News, and Philly.com.
Prior to TRHC, Dr. Knowlton was a key member of the start-up management team of excelleRx, a
hospice medication management and pharmacy distribution company. During her tenure as VP, Chief
Marketing, Strategy, and Business Development Officer, from 1995 through 2007, the company grew
organically to service over 85,000 hospice patients in 49 States. The company was purchased by a
Fortune 500 company in 2005.
Dr. Knowlton has been involved in numerous publications focused on medication safety and personalized
medication management. She has also co-authored the first published consensus guidelines on the
standards for anticoagulation management centers in conjunction with the Anticoagulation Forum. She
has authored and co-authored book chapters and articles focused on marketing pharmaceutical care and
medication therapy management services.
In the community, Dr. Knowlton serves as a Trustee, Executive Committee Secretary, and Chair of the
Governance Committee for Samaritan Hospice, Marlton, NJ. She has served as Trustee for the West
Jersey Chamber Music Society, Moorestown, NJ; Chair of the Medical Committee for the nationally
known American Heart Association’s “Red Dress Luncheon” in Philadelphia, PA; the Dean’s Advisory
Board, School of Public Health, Drexel University, Philadelphia, PA; Dean’s Advisory Board, Jefferson
School of Pharmacy, Philadelphia, PA; Board Member of the George Washington Institute on Spirituality
and Health, Washington, DC; Board Member for Family Services, Westhampton, NJ; and Board Member
of the Perkins Center for the Arts, Moorestown, NJ.
For her professional and personal accomplishments, Dr. Knowlton was named “Woman of Distinction”
2006 by the Philadelphia Business Journal; “NJ’s Best 50 Women in Business 2008” by NJBIZ; winner
of NJ Garden State Entrepreneur Excellence Award 2013 and SNJ Business People “Exceptional
Entrepreneurs Award” 2014. She was named “Citizen of the Year” by the Garden State Council Chapter
of the Boy Scouts of America, 2016, and “Community Partners of the Year” by the Non-profit
Development Center of Southern New Jersey, 2016.
Dr. Knowlton received her Bachelor of Science in Pharmacy and Doctorate in Pharmacy from the
University of the Sciences College of Pharmacy, Philadelphia, PA. She is a graduate of Temple
University’s Fox School of Business Executive MBA program, Philadelphia, PA.
Pauline Corso is Operational Vice President and Chief Operating Officer, Delaware Valley Physician Network for Nemours Children’s Health System, a role she’s held since 2015. Her responsibilities include managing a group of 380 employed physicians across 30 Delaware Valley sites including the Nemours/Alfred I. duPont Hospital for Children in Wilmington, DE. Pauline oversees new and existing partnerships and manages nearly a dozen existing external health organization pediatric partnerships throughout Delaware, Maryland, New Jersey and Pennsylvania. Pauline has been successful at growing innovative programs at Partner hospitals to keep care local. Prior to being named Chief Operating Officer, Pauline served as Physician Practice Administrator for Nemours Delaware Valley. She continues to oversee and manage all aspects of Practice Operations throughout the network.
Pauline is an active member of the American Association of Medical Colleges, Association of Academic Administrators in Pediatrics as well as the American College of Healthcare Executives. Pauline is also an active contributor to professional organizations and conferences around the nation. She has also served on the American Lung Association Mid-Atlantic Board.
Born and raised in Philadelphia, Pauline currently resides in West Deptford, NJ. She holds a Bachelor of Science Degree in Business Administration from Peirce College in Philadelphia where she received the President’s List Achievement Award in Business Administration.
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this, he served as Senior
Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he
served as Group Executive Vice President, Global Business Development and Chief Strategy
Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining, Teva he spent five years as
Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life
sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President,
and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr.
Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global
Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri
also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic
areas upon which the company would focus. His first role at Novartis was as Global Head, Early
Commercial Development - a department he established to ensure the differential competitive
advantage of Novartis' pipeline.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of
Medicine, where he also received his BS in Zoology.
Mr. Sekhri has been a Director on more than 20 private and public company Boards, and is
currently a member of the Board of Directors of Veeva Systems Inc., and Enumeral Biomedical
Holdings, Inc.; Mr. Sekhri is also the Chairman of the Board of Pharming N.V., Petra Pharma, and
Topas Therapeutics GmbH.
Additionally, he serves on several non-profit Boards including the BioExec Institute, Inc., the TB
Alliance, Young Concert Artists, Inc., The English Concert in America (TECA), and the Caramoor
Center for Music and the Arts. Mr. Sekhri also served as a Member of the Board of Trustees of
Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Preston Brice joined MBF Healthcare Partners as a managing director in 2016 and has spent the last 10+ years focused on the healthcare services sector. Most recently he was with Apple Tree Partners (ATP), a $1.5 Bn healthcare focused venture capital/ growth equity fund. During his time at ATP, Preston served as the interim CEO and a Director of Cure Forward (precision medicine technology platform) in addition to being a Board Observer for Clean Slate Addiction Treatment Centers, TripleCare (telemedicine for SNFs) and QualDerm Partners (dermatology practices). Preston has held roles in private equity and investment banking (both M&A as well as leveraged finance) including time at The Beekman Group, a middle market private equity fund, and CIT Group, a middle market investment bank.
Preston earned his M.B.A. from Columbia Business School, where he achieved Dean’s Honors and Distinction and holds a B.S. in Business Administration from Boston University’s School of Management where he graduated magna cum laude.
MBF Healthcare Partners is a healthcare focused private equity fund specializing in strategic growth equity investments and majority recapitalizations of middle market companies. Founded by successful operating executives, we not only understand the day to day challenges of growing a business but also have deep insights into what it takes to succeed in today’s shift to value based care. We are actively looking for executives with whom to partner as we deploy our second fund. Our target initial equity check is $20MM to $50MM per deal.
Mr. Ram Mukunda, has served as our Executive Chairman, Chief Executive Officer, and President since our inception on April 29, 2005.
Ram Mukunda is responsible for the Company’s thrust into medical cannabis. He has spent the past four years studying the medical cannabis industry and has assembled an impressive team of advisors with deep backgrounds in immunology, neurology, plant genomics, cannabis metabolism, and extraction technologies.
From January 1990 to May 2004, Ram Mukunda served as founder, Chairman, and Chief Executive Officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure-play international long distance carrier. Ram Mukunda was responsible for organizing, structuring, and integrating a number of companies owned by Startec. Under Mr. Mukunda’s tenure at Startec, the company made an initial public offering of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.
Ram Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs.
Mr. Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland’s International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP’s Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.
Randy Oostra, DM, FACHE (62), is the President and Chief Executive
Officer of ProMedica, a non-profit, mission based health system based
in Toledo. ProMedica has more than 17,000 employees and more than
2,300 physicians with 900 healthcare providers employed by ProMedica
Physicians. Its 13 hospitals and more than 300 facilities offer comprehensive diagnostic, medical
and surgical specialties in heart and vascular, oncology, orthopedics, neurology, and women
and pediatric services. Forbes has selected ProMedica for its 2017 list of America's Best
Employers and Truven Health Analytics, part of the IBM Watson Health business, has listed
ProMedica in the top quintile for a top performing health system.
In addition to President and CEO, he has held numerous roles at ProMedica since joining the
system in 1997 including: President and Chief Operating Officer (2006 - 2009), Regional
President (2002 – 2006), and Corporate Vice President, Strategic Business Development (1998 –
2006). Prior to joining ProMedica, Randy served in myriad roles in health care leadership,
including: Saint Anthony’s Health System, Alton, Illinois (1994 – 1997); Blodgett Memorial
Medical Center, Grand Rapids, Michigan (1989 – 1994); Health One Corporation, Minneapolis,
Minnesota (1987 – 1989); and LCM, Sioux Falls, South Dakota (1982 – 1987).
Randy holds a Doctorate in Management from Case Western Reserve University; a Master’s
degree in Health Care Administration from the University of Minnesota; a Master’s degree in
Management from the University of Wisconsin; and a Bachelor of Science degree in Biology
from Northwestern College, Orange City, Iowa. Randy has been recognized by Becker’s
receiving the Healthcare Leadership Award and was named by Modern Healthcare 100 most
influential people in healthcare for 2017.
Randy’s commitment to the healthcare industry, and community, is evidenced in his extensive
involvement in numerous professional and civic organizations at the local, regional and national
levels. He is a board member of the American Hospital Association; Health Research &
Educational Trust (HRET) Board member; a member of the Ohio and Michigan Hospital
Associations; is a fellow with the American College of Healthcare Executives. He is a Board
Member of the Regional Growth Partnership, Toledo Art Museum, Northwestern College
(Iowa), the Development Committee for Bread for the World, chaired the 22 nd Century
Committee and is currently the Board Chair for the Toledo Symphony and the Downtown
Randy and his wife, Barbara, have three grown sons. In addition to spending time with his
family, Randy’s interests include running, golfing, traveling and reading.
As a transformation leader in biotech and pharma, Rich Daly has a proven record
in establishing start-ups, building high growth businesses, and in turnaround
situations. He is known for his ability to tackle tough jobs and deliver big results.
His versatile skills encompass P&L accountability, R&D/commercial integration,
business development, acquisitions, emerging market development, and strategic
partnership management. His experience spans Cancer, Arthritis, GI, Diabetes,
Chronic Kidney Disease/Renal, Cardiovascular, and Oncology segments.
Currently, Rich is Chairman and CEO of Neuralstem (NASDAQ: CUR), a clinical stage CSN company. Since
joining the company in February, 2016, Rich has clarified their strategy, streamlined operations, and raised
$45 million in equity financing to enable completion of their leading clinical/pre-clinical programs as well as
strengthen their shareholder base.
Between 2014 and 2016, Rich was the Managing Partner of Ravine Rock Partners, a management
consulting firm focused on transformational performance, from start-up/biotechs to top-tier clients.
Consultancy revenues grew 100%+ for 3 consecutive quarters and the client base tripled over 6-months.
In 2013, a $1.3 billion, 3,000-employee Diabetes subsidiary of AstraZeneca Pharmaceutical recruited Rich
as their President. Within 12 months, he transformed the poorest performing U.S. diabetes portfolio into the
fastest growing. Sales and profits increased 15% and 7%, respectively, through increased collaboration,
clarifying accountability, and targeted resource allocation.
Rich’s entrepreneurial passion was ignited in 2011 when he, with some close colleagues, formed and
operated Sagepath Partners, an outsourced commercial services company to increase the efficiency of the
pharmaceutical industry. By 2013, the management team orchestrated a successful sale to Ashfield
Commercial & Medical Services.
From 2008 to 2011, Rich served as Executive Vice President of Takeda Pharmaceuticals North America
(“TPNA”) with P&L responsibility for $4 billion in revenues. To accelerate growth, he invested over
$150 million and built three fully functional companies: Takeda Mexico, Takeda Canada, and Takeda Brazil.
In addition, he built the business development function within 60 days, pioneered greater use of in-licensing,
drove accretive acquisitions, and managed 3 launched products with a $1 billion in market potential.
Early in his career he joined TAP Pharmaceuticals, a joint venture between Takeda and Abbott in 1991.
Over the next seven years, TAP expanded rapidly through organic growth and business development and
enabled Rich’s commercial expertise to flourish through every facet of marketing including the launch of their
a blockbuster product, Prevacid, that achieved over $3 billion in sales annually.
In 1998, Rich joined the start-up company TPNA as its 14 th employee and a member of the core leadership
team. His responsibility expanded from Senior Director of Marketing to Vice President of Marketing and,
ultimately, Senior Vice President of Marketing and Business Development. Under his guidance, the Actos
product launch attained $950 million in sales within three years and became one of the most successful
product launches in pharmaceutical history.
Rich earned his MBA at Northwestern’s Kellogg School of Management and achieved his Bachelor of
Science degree in Microbiology at the University of Notre Dame, where he twice earned All-American honors
He currently serves on the Board of Directors for Neuralstem (NASDAQ: CUR), Catalyst Pharma (NASDAQ:
CPRX), and Synergy Pharmaceuticals (NASDAQ: SGYP).
Rich lives with his wife Susan and their two sons in Lake Forest, Illinois.
Richard Peters, M.D., Ph.D. has served as our President and Chief Executive Officer since February 2017. Dr. Peters previously served as Senior Vice President and Head of Global Rare Diseases at Sanofi Genzyme, where he was responsible for a global, $3 billion per year business with 10 commercialized products and a multi-product development pipeline focused on several therapeutic areas. He also served as Head of Japan and Asia Pacific for Specialty Care (Oncology, Rare Diseases, Immunology and Multiple Sclerosis) at Sanofi Genzyme. He is an expert in the field of Oncology, having previously served as Division Medical Officer at Sanofi Oncology and is the former Head of Global and US Medical Affairs at Genzyme Transplant/Oncology. He has also served as a Senior Director at Onyx Pharmaceuticals, as a Director at Amgen and as Chief Executive Officer of Mednav, a venture capital-backed healthcare information technology start-up. Dr. Peters is a Harvard-trained physician-scientist and has served on the faculty at the Massachusetts General Hospital and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. He is also an active founder and angel biotech investor in start-up biopharmaceutical companies.
Rick Mangat, Ph.D. has been the Chief Executive Officer and President of NOVADAQ Technologies Inc. since July 2016.
Prior to that, Rick served as Senior Vice President and General Manager of NOVADAQ. He also held positions as Vice
President of Operations and Director of NOVADAQ.
Rick Mangat co-founded NOVADAQ in April of 2000 and is a co-inventor of the SPY System. The research element of his
Ph.D. thesis (Pharmacology and Therapeutics) performed at the National Research Council of Canada (Institute for
Biodiagnostics) formed the foundation for the SPY System and related intellectual property. Rick received his B.Sc. from
the University of Toronto and his Ph.D. from the University of Manitoba.
Risa leads the GE Ventures, New Business Creation team. The team has started companies in healthcare and other industries including: Evidation Health, Vineti, Avitas Systems, Current powered by GE, and Menlo Microsystems. Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT). Risa holds a degree in genetics and development with distinction from the University of Illinois, a Ph.D. in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.
Robert Blum has been President and CEO of Cytokinetics since 2007 and previously held roles of
increasing responsibility since starting the company in 1998. Previously, Robert led Business
Development and Commercial Development functions at COR Therapeutics from 1990-1998 and
began his industry career at Syntex Corporation (Roche) and Marion Laboratories (Sanofi).
Robert served on the faculty at the Center for BioEntrepreneurship at UC San Francisco. He co-
chaired the BIO Business Development Committee and has been an investor/consultant to
emerging biopharmaceutical companies for over 30 years. Mr. Blum served on the National
Board of the American Committee of the Weizmann Institute of Science and established the
Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute
directed to incubate start-up’s and propel innovation for the Israeli life sciences economy. In
addition, he established the Tikkun Olam Youth Science Prizes for Bay Area schools designed to
further science education in the spirit of repairing the world. Robert served on the Board of the
Jewish Community Federation of San Francisco and founded and chaired its Business Leadership
Council. He also served on the Boards of San Francisco's Contemporary Jewish Museum and the
Anti-Defamation League and now serves on the Board of Jewish Children and Family Services of
San Francisco. Robert was named a Henry Crown Fellow of the Aspen Institute and is a member
of the Aspen Global Leadership Network. Mr. Blum received B.A. degrees in Human Biology
and Economics from Stanford University and an M.B.A. from Harvard Business School.
Mr. Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx
Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at
Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became
the top performing IPO; raised over $780M from private and public sources; achieved FDA approval
and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the
Elacestrant oncology program. Prior to joining Radius, Mr. Ward held a series of progressive
management and executive roles with established companies such as NPS Pharmaceuticals,
Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has
been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance
Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward
serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in
Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara,
an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology
from the John Hopkins University School of Medicine.
Robert L. Gershon, former CEO and Director of Bovie Medical Corporation (NYSE: BVX), has
over 29 years of healthcare industry experience. Under his 4 years of leadership Bovie Medical
grew over 65% and increased its market cap three-fold. Prior to Bovie, he ran the largest sales
and marketing business at Covidien. With over $1B in P&L responsibility he consistently led an
organization of over 600 people to double-digit revenue growth outpacing market category
growth and capturing significant market share points during challenging healthcare economic
conditions. He also was VP of sales and marketing at Henry Schein ($1.4B shared P&L for
medical division/$115M full P&L for dialysis division) and earlier in his career spent over 13
years as a healthcare consultant for Booz, Allen, KPMG and two boutique consultancies where
his practice focused on strategic planning, business development and mergers and acquisitions.
Mr. Gershon received an MBA from J.L. Kellogg Graduate School of Management at
Northwestern University and a BSBA degree (finance major) from The American University.
Rodney Dean Reider serves as President and CEO of Saint
Alphonsus Health System, a multi-hospital and clinically-
integrated healthcare system serving Southwestern Idaho
and Eastern Oregon. Mr. Reider provides vision and
leadership in the transformation of the organization to a
people-centered Health System. Under Mr. Reider's
leadership the health system places the people they serve at
the center of every decision as they work to improve quality,
the experience of care, and the health of our communities.
Previously, Mr. Reider served in healthcare leadership as Vice President, Aurora St.
Luke's Medical Center in Milwaukee, WI; President and CEO, Community Health
Systems/University of Pennsylvania Health System in Philadelphia, PA; as well as
several other President and CEO positions prior. Mr. Reider received his MBA at Loma
Linda University; his Masters of Science at Cal Poly Pomona Harrison; and he has a
Master of Arts and Doctorate from Harrison Middleton University. He has studied as an
international scholar studying healthcare and business in both Western Australia and
Salzburg, Austria. He is a Fellow of the American College of Healthcare Executives.
Locally, Mr. Reider is involved in critical community strategies, such as the City of
Boise's Housing First Initiative, which will transition the chronically homeless to a stable
housing environment. Saint Alphonsus is a major funder of the project and will be
providing health care to the residents once the project is operational.
Mr. Reider has also been inducted into the 124 th Fighter Wing of the Idaho National
Guard as an honorary commander. In that position, he is supporting the important role
the National Guard has throughout the State of Idaho and the local community. Saint
Alphonsus works with to support and train as well as employ numerous Idaho National
Guard members in our area hospitals and clinics.
In 2017, Mr. Reider was selected as one of 10 "CEO's of Influence" in the business and
non-profit sectors in Idaho by the Idaho Business Review.
Mr. Rongen is a Co-Founder of Matinas BioPharma and the Chief Executive Officer. He is also the Founder and Chairman of Essential Fatty Acid Therapeutics, a biotech company focused on the development of innovative fatty acid derivatives. Prior to Matinas BioPharma, Mr. Rongen was Executive Vice President North American Operations for EPAX/Trygg Pharma and Vice President of Life Cycle Management and Intellectual Property at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. While at Reliant, Mr. Rongen held various earlier positions, including head of the Omacor®/Lovaza® launch team, Executive Director of Marketing for Lescol® and Executive Director of Business Development. Before Reliant, Mr. Rongen was Global Product Director for Humira® at BASF Pharmaceuticals, later acquired by Abbott. He was also a consultant at The Wilkerson Group in New York and with Arthur D. Little in Amsterdam. Mr. Rongen earned an MBA from Kellogg GSM at Northwestern University, and a graduate degree in Molecular Sciences from Wageningen University in the Netherlands.
Sabrina Martucci Johnson is the Founder and CEO of DARÉ Bioscience (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health. Prior to founding DARÉ, Sabrina was President of WomanCare Global Trading, a global provider of women’s health products, and CFO/CAO of the California Institute for Biomedical Research. She served as COO and CFO of Cypress Bioscience, Inc. (NASDAQ:CYPB) until its sale in 2010 and also held positions with Advanced Tissue Sciences and Clonetics Corporation. She began her career in the biotechnology industry as a research scientist with Baxter Healthcare.
In the community Sabrina serves on the board of organizations that advance the economic well-being and health of women and girls and promote education. She serves on the YWCA of San Diego County Board of Directors as immediate past-president, Clearity Foundation Board of Directors, Athena Board of Directors as Co-Chair, PPPSW Board of Directors, Tulane University School of Science & Engineering Board of Advisors, University California San Diego Librarian’s Advisory Board, Project Concern International Audit Committee, and Sabrina is the immediate past co-president of Women Give San Diego.
Sabrina has a Master of International Management with honors from the American Graduate School of International Management (Thunderbird); a MSc. in Biochemical Engineering from the University of London, University College London; and a BSc. in Biomedical Engineering from Tulane University, magna cum laude.
As chief executive officer of Magellan Healthcare, Sam Srivastava focuses on improving health and affordability through advanced analytics and clinical solutions. He leads the strategy development, operations, product development and management, and profitability and growth of Magellan Healthcare, while positioning Magellan as a leader in the behavioral health, Medicaid and specialty healthcare markets. Srivastava also provides leadership over enterprise strategy, communication and government affairs. Prior to joining Magellan, Srivastava worked at Cigna where he was president of the national and senior business segments. He had executive management responsibility for the strategic planning, business operations, growth and financial performance for these segments, which serve approximately 18 million individuals. He was instrumental in the acquisition of HealthSpring and the pharmacy benefit management partnership with CatamaranRx. Srivastava has held executive leadership positions in the commercial, senior, low-income and disabled population segments at UnitedHealth Group and HealthNet, and served as a management consultant in the United States and internationally, primarily focusing on the areas of developing and improving integrated health care delivery systems for providers, insurers and governments. Srivastava graduated from Kent State University with a bachelors degree in medical science and humanities, and completed graduate work at Yale University in healthcare management. He also sits on a number of advisory boards, including Oliver Wyman, Yale School of Public Health and Yale Healthcare Conference. He is married to Dr. Lisbet Lundsberg, a member of the faculty at the Yale School of Medicine, and resides in Wilton, Conn. with their four daughters.
Dr. Shantanu Gaur is the co-founder and CEO of Allurion Technologies. Together with his partners, Shantanu has overseen Allurion’s research and development, fundraising, and clinical programs. Allurion’s mission is to help people realize their full potential with innovative, scalable, and trusted products. Specifically, the company has developed what Shantanu calls “Weight Loss 2.0” products that are more effective than diet and exercise but safer, cheaper, and more accessible than weight loss surgery. Allurion’s flagship product—the Elipse® Balloon—is the world’s first and only procedureless gastric balloon for weight loss and is now available for commercial sale internationally.
Shantanu is the lead inventor on several US and international patents and has authored multiple peer-reviewed publications. He has been invited to speak on the Elipse Balloon, obesity, and medical device innovation at several worldwide congresses and has also spoken widely on the use of crowdsourcing to make research more efficient and participant-centric. Shantanu is also a lecturer for Harvard Medical School’s Executive Education program where he has been invited to speak on new frontiers in medical device development.
Shantanu graduated summa cum laude with a B.S. in Biology from Harvard College and with an M.D. from Harvard Medical School where he was a Paul Revere Frothingham Scholar and Paul & Daisy Soros Fellow. He lives in Boston, MA with his wife Neha and son Yuvraj.
Dr. Steve Allen has been CEO of Nationwide Children’s Hospital since July 2006. Dr. Allen is credited with leading the organization’s prominence as a national and international leader in pediatric healthcare and research. With more than 1 million patient visits each year, Nationwide Children’s is a global healthcare destination with children referred for treatment from all 50 states and more than 41 nations worldwide. The hospital’s outstanding medical staff is recognized for excellence in a wide range of clinical specialties and research discoveries. US News and World Report have consistently named Nationwide Children’s Hospital to their Honor Roll as one of the best children’s hospitals in America.
Prior to coming to Columbus, Steve was a physician, scientist, teacher and executive in the Texas Medical Center in Houston for 24 years. He has published over 100 articles and more than 20 book chapters on a variety of medical topics. He is board-certified in Anesthesiology and Critical Care Medicine and awarded an MBA. He serves on a number of community boards, as well as the past chair for the Children’s Hospital Association board. He is married to Dr. Jamie Allen and has five children.
Steven A. Kriegsman, Mr. Kriegsman has been CytRx Corporation's President and Chief Executive Officer
and a director since July 2002, and Chairman of the Board since 2014. He also serves as a director of Galena
Biopharma, Inc. (Nasdaq: GALE) and Chairman of Galena’s Compensation and Transaction Committees. He
previously served as Director and Chairman of Global Genomics from June 2000. Mr. Kriegsman is an inactive
Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development
of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised
such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences,
and Maxim Pharmaceuticals. Mr. Kriegsman has a BS degree with honors from New York University in Accounting
and completed the Executive Program in Mergers and Acquisitions at New York University, The Management
Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors' College. Mr Kriegsman was formerly a
Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of
the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the company has since been sold). In February 2006,
Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of
the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the
Muscular Dystrophy Association. Mr. Kriegsman has been a guest speaker and lecturer at various universities
including California Institute of Technology (Caltech), Brown University and New York University. Mr. Kriegsman
has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS
Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California
Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
Steven Krein is the CEO and co-founder of StartUp Health, which is organizing and supporting a global army of Health Transformers. StartUp Health has the world’s largest digital health portfolio at nearly 200 companies spanning 18 countries and 65+ cities.
Prior to StartUp Health, Steven co-founded and led several technology companies including OrganizedWisdom, Promotions.com and Webstakes, a global online advertising, direct marketing, and technology company, which he took public on Nasdaq and grew to a $500M market cap before it was acquired by iVillage in 2002. Steven began his online career with Law Journal Extra!, now known as Law.com, the first online legal news and information website.
Steven is a serial entrepreneur, speaker, investor, advisor and entrepreneurial coach. Steven has been a keynote speaker at events hosted by Children’s Hospital Colorado, Cleveland Clinic, Google, Johnson & Johnson, Lake Nona Institute, McKinsey, Slush and Wharton, among others and has been a guest on Bloomberg TV, CNBC, CNN, FOX Business and The Today Show.
Steven received his JD degree from Delaware Law School and BA degree from the University of Maryland, College Park. Steven is a member of YPO (Young Presidents’ Organization) Metro New York Chapter and lives in New York City with his wife and three daughters. Follow him on Twitter @stevenkrein.
Steven H. Stein, MD is the Chief Medical Officer at Incyte Corporation. In this role, Dr. Steins primary responsibility is leading all the medical and scientific activities involving clinical development, clinical operations, pharmacovigilance, clinical pharmacology, scientific communications and medical affairs at Incyte Dr. Stein previously worked at Novartis Oncology as the Senior Vice President and Head of U.S. Clinical Development and Medical Affairs and prior to that at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his MBBCH from the University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein is also an active member of several professional and scientific societies and academic committees.
Stuart Rose founded The BioScience Center in Albuquerque in 2012. Dr. Rose is a serial entrepreneur with more than four decades in the pharmaceutical manufacturing industry and the host of more than 20 startups developing vaccines, medical devices and research tools. His most recent endeavor is PaizaBio, a joint venture with a Chinese partner. China represents an unparalleled growth opportunity for Western pharmaceutical companies. While its not uncommon for Western companies to have a manufacturing presence in solid and oral drug manufacturing in China, the aseptic injectables market has remained elusive, restricted to imports and leaving the market untapped for domestic sourcing. This need resulted in the partnership and PaizaBio. In 2014, Dr. Rose also opened FatPipe ABQ as a privately funded collaborative work space providing amazing internet bandwidth speeds, program and training for entrepreneurs, and his advice and guidance to any startup that asks for it. Stuart's approach to supporting the entrepreneurial ecosystem is unique. He believes the private sector needs to take the lead and has proven so by investing in his city's startup culture.
Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.
Wa’el Hashad joined Avanir as President and Chief Executive Officer in July 2017.
Wa’el is a passionate leader with over 25 years of pharmaceutical experience in sales,
marketing and general management, within both the U.S. and international markets.
Most recently, he served as Executive Vice President and Chief Commercial Officer of
Seres Therapeutics, where he spearheaded the strategy and development of several
Prior to Seres, Wa’el held several roles at Amgen, Inc. which included Head of Global
Marketing and Therapeutic Area Head for General Medicine, Regional Vice President of
Japan, China, and Asia-Pacific, and Regional Vice President for Africa and the Middle
East regions. Earlier in his career, Wa’el served as Vice President of Cardiovascular
and Diabetes Business at Boehringer Ingelheim and he also spent 18 years at Eli Lilly
and Company where he was responsible for the successful launch of several products.
Wa’el earned his BSc in Pharmacy and Pharmaceutical Sciences from the College of
Pharmacy, Cairo University, and his MBA from the University of Akron in Ohio.
Wolfgang Söhngen is founder and CEO of PAION AG and Managing Director of
PAION Deutschland GmbH. He has raised more than EUR 180 million through fund
raising and EUR 88 million through partnering.
Wolfgang has many years of experience in the pharmaceutical industry. He worked in
clinical development, project management, corporate development, and strategic
planning at Grünenthal GmbH for ten years. Before founding PAION in 2000 with his
wife Mariola, he was head of his own consulting firm, Virtueality, which specialized in
healthcare and clinical development.
In 1985, Wolfgang received his doctoral degree in medicine from RWTH Aachen
(Technical University of Aachen). He spent two years as a resident in internal
medicine and was then offered a post-doc position in cardiovascular pharmacology at
the University of Michigan, Ann Arbor (USA). He also holds a Master of Business
Communication and a Diploma in Pharmaceutical Medicine (DGPharMed).
Zack Irani-Cohen - Chairman and Chief Executive Officer of Biomerica Inc. (Nasdaq: BMRA) a
global biomedical company that develops, manufactures and markets advanced diagnostic
products used at the point-of- care and in hospital/clinical laboratories for the early detection of
medical conditions and diseases. Biomerica’s InFoods® IBS product is designed to allow
physicians to identify patient specific foods (e.g. eggs, milk, wheat, sugar, corn, etc.), that when
removed, may alleviate or improve an individual's IBS symptoms. The InFoods® IBS product is
intended to be used in conjunction with current pharmacotherapy to improve outcomes in the
over 45 million Americans that are affected by IBS.
Zack is also the managing partner of T&T investment group (a real estate investment fund
focused on multi-tenant apartment buildings in California) and a board member/investor in a
Biospecimen Technologies and Oryn Therapeutics. Previously he served as the CEO and
Chairman of Lancer Orthodontics, Inc., an international manufacturer of orthodontic products.
Mr. Irani-Cohen earned an MBA from the University of California, Irvine, in 1994, and graduated
from Chapman University with a B.S. in Business, in 1988. He is a member of YPO International.
His interests and hobbies include: Surfing, kite surfing, performing music, real estate
investments, and various philanthropy projects.
Dr. Neuwirth began his career as an academic general internist with a particular focus on healthcare communication and relationship- centered care. His articles on humanism in health care have been published in medical journals as well as in the New York Times and Newsweek; and his efforts to improve healthcare delivery have also been featured in Forbes, Fast Company, WebMD, the Yale School of Management Journal, The Boston Globe and The Charlotte Observer. Zeev currently serves as Senior Medical Director of Primary Care within the Carolinas Healthcare System Medical Group a 1900 provider multi-specialty network. In addition, he is an executive leader for core strategic initiatives focused on Population Health Management, Payment Alignment, Primary & Specialty Care Redesign, Corporate Health, and Retail Medicine. Dr. Neuwirth has been deeply engaged in community health and mHealth innovations while at Carolinas. In 2012, he was selected as one of 70 participants from a pool of over 1000 applicants, into the CMMS Innovation Fellows program. In 2014, he received an Innovation in Healthcare award from the Charlotte Business Journal. He currently functions as an advisor to a number of healthcare start-ups. Prior to his current role at Carolinas, Zeev served as Chief of Clinical Effectiveness & Innovation at Harvard Vanguard Medical Associates, a 600 physician multi-specialty practice located in Eastern Massachusetts. In 2011, during his tenure at Harvard Vanguard, Zeev received the first Mayoral Award for Innovation in Healthcare from then Boston Mayor, Thomas Menino. Zeev attended Tufts University undergrad, The University of Pennsylvania School of Medicine, and completed his internship and residency in Internal Medicine at the Mount Sinai Hospital in Manhattan. In addition to his medical training, Dr. Neuwirth is a certified family and group therapist, having trained at the renowned Ackerman Institute for the Family. He holds a Masters degree in Health Care Management from the Harvard School of Public Health where he has also taught courses on health care strategy to physician executives in a Masters level program.
Currently a consultant to the biopharmaceutical industry, Mr. Klausner most recently served as CEO and a Boardmember of Gem Pharmaceuticals (non-cardiotoxic doxorubicin analog vs. cancer that was acquired by Monopar Therapeutics in 2017), and he was previously CEO and a Boardmember of Jade Therapeutics (ophthalmic applications of a cross-linked hyaluronic acid polymer that was acquired by EyeGate Pharmaceuticals in 2016).
Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. Klausner has been a board member at Santarus (IPO in 2004), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007), and Syndax Pharmaceuticals (IPO in 2016), and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007). He currently serves on the Board of Directors of Monopar Therapeutics and Cennerv Pharma (Singapore), and on Advisory Boards for Neurotez and the New York University Innovation Venture Fund.
Klausner began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business. While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems and Neurogen, two startup biopharmaceutical companies that subsequently went public. Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies. His undergraduate degree in Biology is from Princeton University.
Brett R. Friedman has experience advising a broad spectrum of clients on a variety of complex transactional, enforcement and regulatory matters within the health care industry. His clients include hospitals, managed care plans, pharmacy and dental benefit managers, pharmaceutical and device manufacturers and community-based providers of care to persons with mental illness and developmental disabilities. He routinely advises clients in responding to government investigations and audits concerning potential violations of health care fraud and abuse laws; maintaining regulatory compliance; and structuring innovative arrangements involving the development of integrated health care delivery networks in connection with value-based payment models.
Cliff co-founded Cornerstone Search Group (Cornerstone) in 2000. He is a Managing Partner of the firm and actively leads and conducts executive search assignments for small, medium and large global pharmaceutical and biotechnology companies.
In addition to managing the day-to-day activities of Cornerstone, Cliff also heads-up Cornerstone’s MD/Physician specialty practice area that fills key positions that require and/or highly prefer MDs/Physicians for positions in the following areas:
⦁ Leadership (CxO, Global TA Heads, Global Functional Heads etc.)
⦁ Clinical Development for both early Phase 1/FIH through Phase 2/PoC development programs, and later-stage Phase 3/registrational development programs
⦁ Medical Affairs (pre-launch planning, launch and lifecycle management)
⦁ Drug Safety/Pharmacovigilance/Risk Management
Cliff has successfully planned, conducted and filled multiple Retained Searches at all levels in Cornerstone’s areas of emphasis and expertise, which include the following:
⦁ Clinical Development
⦁ Medical Affairs
⦁ Safety/PVG/Risk Management
⦁ Market Access
⦁ Health Economics and Outcomes Research (HEOR)
⦁ Clinical Operations
⦁ Project Management
Cliff started his career in the executive search industry in 1983. Prior to working in the executive search industry, Cliff worked as a Certified Public Accountant (CPA) for a Fortune 500 Company (Duke Energy), a Top-tier Global Management Consulting Firm (Booz | Allen | Hamilton) and a prominent Certified Public Accounting Firm (Wiss & Company, LLP)
Cliff is a graduate of Montclair State University where he earned a BS degree in Business Administration and a BA degree in Economics.
Cliff is a charter and active member of the International Retained Search Associates organization (IRSA) that is a global executive search organization with 31 offices located throughout the US, Canada, EU, China and Malaysia. He is the past President of the New Jersey Chapter of ACRP (Association of Clinical Research Professionals).
Dr. Esteban Pombo-Villar, is Chief Executive Officer of TargImmune Therapeutics, a biopharmaceutical company focused on the development of novel immuno-oncology therapeutics, based in Basel, Switzerland. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR). Prior to that he served in several roles as medicinal chemist in the Neuroscience research group. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was a visiting researcher at the University of Newcastle upon Tyne (UK), and completed postdoctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, member of several scientific societies and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US). A native of Bogotá, Colombia, he lives in Switzerland since 1986.
Jason Rifkin is President and CEO of AAVP Biosystems, Inc., a targeted gene therapy company developing therapeutics for oncology. Jason has spent his career managing early drug development programs through important pre-commercial inflection points and milestones. He has held a number of positions in biotechnology and medical device companies, leading efforts in clinical operations, scientific affairs, business development, operations, as well as product launches. Previously, Jason was President of PreScience Labs, LLC, an oncology focused company developing a glycolysis inhibitor and prior to that, he held a variety of roles at Delcath Systems, Inc., including Senior Vice President of Clinical Affairs where he oversaw the company’s Phase III and II development programs for its proprietary drug delivery system in oncology indications. In each role Jason fills, he executes both strategic and tactical initiatives to increase company valuation early in the development pathway, validating technologies through pre-clinical and clinical milestones. Jason earned a Master’s of Science in Biotechnology from The University of Pennsylvania, School of Engineering and Applied Science, a Juris Doctor from Northeastern University School of Law, and a Bachelor of Science from The University of Pennsylvania.
Jeffrey C. Thrope is a partner and health care business lawyer with Foley & Lardner LLP. Mr. Thrope has a broad range of experience as a general counsel to the health care and related industries, as well as not-for-profit organizations and governments. He is a member of the Health Care Industry Team, as well as the Public Finance Practice.
In addition to his considerable experience in helping public and safety-net hospitals develop operational and financing plans necessary to their survival, Mr. Thrope has provided advice and counsel in virtually every area of health care law, including health care institutional structuring and governance, compliance, network formation, litigation oversight, medical-legal and ethical issues, contracting, high technology acquisition and implementation, Internet and e-commerce activities, bank financing, reimbursement, dispute resolution (including litigation where necessary), labor, internal investigations, physician arrangements and credentialing and related matters. Mr. Thrope was instrumental in developing and implementing structures for the assisted living industry as it expanded into New York.
Mr. Thrope has provided similar services to governments, colleges and other not-for-profit entities in the educational field, and has a particular talent for helping maintain his clients’ mission, while addressing whatever legal issues they face. He has helped governments address structuring and financial issues, and has identified significant revenue and cost containment opportunities that have become more critical in these difficult times.
Prior to joining Foley, Mr. Thrope was a partner at Kalkines, Arky, Zall & Bernstein LLP (1988 to 2002), and then at Manatt, Phelps & Phillips, LLP (2003 to 2009). He was an associate and partner at other firms from (1981-1987).
Mr. Thrope has spoken at various conferences and has contributed to course materials, including the Practicing Law Institute Faculty 1999: Understanding, Preventing and Litigating Year 2000 Issues - Health Care Industry.
Mr. Thrope is a graduate of New York University School of Law (J.D., 1980), where he was a member of the Law Review, and a graduate of Yale University (B.A. 1977).
Mr. Thrope served as a law clerk to the Honorable Leonard B. Sand, Unites States District Court Judge for the Southern District of New York (1980-1981).
Mr. Thrope also has served as a member of the Health Law and Family Courts Committees of the Association of the Bar of City of New York.
Mr. Thrope was admitted to the New York Bar in 1981, and is admitted to practice in the federal courts for the Southern and Eastern Districts of New York and before the Second Circuit Court of Appeals.
Lawrence Obstfeld is CEO of Image Navigation which has developed the FDA-approved IGI system for CT-navigated oral-maxillofacial surgery and the DentSim - augmented reality dental simulator. Also a founder of BetaGene, Inc. and Gladius Pharmaceuticals.
Lawrence Vernaglia is a partner and health care lawyer with Foley & Lardner LLP and serves as chair of the firm’s Health Care Practice and co-chair of the Health Care Industry Team – named “Health Law Firm of the Year” by U.S. News - Best Lawyers® on the "Best Law Firms" list (2012 – 2014). Mr. Vernaglia represents hospitals, health systems and academic medical centers and a variety of other health care providers. Mr. Vernaglia's practice involves regulatory and transactional matters, including Medicare/Medicaid reimbursement compliance advice and appeals; mergers, acquisitions and financings; state regulatory issues including licensing, change of ownership, and CoN/DoN; survey/certification appeals; fraud & abuse/Stark law analyses; managed care contracting; and general corporate and business planning in health care. He runs strategic planning programs for senior management and governing boards. He regularly serves as local counsel on health care transactions in New England for multi-state projects.
Mr. Vernaglia is the past co-chair of the Boston Bar Association's Health Law Section (2006-2008 term). He serves on the editorial boards of JONA's Journal of Healthcare Law, Ethics, & Regulation; and Medicine & Health/Rhode Island. Mr. Vernaglia is one of nine members of the Medical Economics' Board of Legal Editorial Consultants and for several years, he has been co-chair of MCLE's comprehensive Health Law Basics program and the advanced Health Law Conference. He is involved with several not-for-profit organizations as a board member and legal advisor.
Mr. Vernaglia is the co-editor of the book Healthcare Compliance Professional's Guide to the False Claims Act (2007). He is also the co-editor of the two volume treatise Massachusetts Health and Hospital Law Manual (2004, 2009, 2012). He has published more than 40 articles and book chapters on various topics in law and medicine in such sources as AHLA's Health Law Digest and Health Lawyers Weekly; Medical Economics; The Journal of Health Care Finance; The Boston Business Journal; and Health Care Policy Report.
He is a regular lecturer on hospital issues, physicians, long term care, and other topics in law and medicine. Speeches by Mr. Vernaglia addressed topics such as: accountable care organizations (ACOs); physician/hospital joint ventures; discount/collection policies for uninsured patients; the Anti-kickback Statute; corporate governance for nonprofits; the board of directors’ role in compliance; reimbursement and managed care; and HIPAA.
Mr. Vernaglia earned his J.D. and his master's in public health from Boston University and his bachelor's degree from New College of Florida. He is admitted to practice in Massachusetts, New York and New Hampshire.
Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
Rami founded Telesofia Medical (MyOp.md), combining his passions to medicine and technology.
He has over 20 years of experience in the Internet industry. He started his career in 1997 at ICQ (formerly Mirabilis, acquired by AOL in 1998, for US$407 million) in various roles including Director of Web Operations. Since 2001, he helped several companies and start-ups with product development, launching and marketing in the online world. As VP Operations at Novawind, he provided Hands-On marketing, business development, and innovation management services for leading companies.
Rami also holds a medical doctor degree from the Tel Aviv University and worked at the Vascular Surgery department in Tel-Aviv Sourasky (Ichilov) Medical Center and Assaf Harofeh Medical Center.
Richard Lipkin is a Managing Director of Easton. Previously, he was a partner of Commerce Health Ventures, a life sciences healthcare fund, and Laird & Co., a private merchant bank; a biotech analyst consultant for a Goldman Sachs hedge fund and for DARPA; Executive Director of the Strang Cancer Prevention Center; and a prolific author, awarded the American Chemical Society’s Grady-Stack Award for research analysis. He studied theoretical neuroscience at Columbia University, and serves on many boards, councils, and committees for the Weizmann Institute of Science, Rockefeller and Columbia Universities, MBL, NYAS, and Montefiore Medical Center. He is an honors graduate of Princeton University, has an MBA from Columbia, and is a Senior Staff Associate in Columbia’s Dept. of Neuroscience.
Roger is a Board-certified Medical Oncologist with over 20 years’ experience supervising the delivery of complex oncology patient care and palliative medicine in teaching hospitals and developing new drugs in oncology and in malaria at large pharma. Roger is the Chief Medical Officer of Rgenix, Inc. a New York City-based cancer therapeutics company developing first-in-class drug candidates.
Prior to joining Rgenix, Roger was the CMO/CSO for Napo Pharmaceuticals and Jaguar Health, developing first-in-class, FDA-approved botanicals as novel antidiarrheals. Roger spent over nine years at Novartis, most recently as Global Program Head responsible for all early and late-stage development activities of antimalarials, including Coartem and two compounds in Phase 2 development, including generating a collaboration agreement with Medicines for Malaria Venture and the Bill and Melinda Gates Foundation. Previously, Roger was responsible for Global Clinical Development activities for several oncology compounds including the successful NDA filing of Jakavi, and sNDA’s for Tasigna and Glivec.
For nearly 12 years, Roger worked as a clinical medical oncologist and clinical researcher at Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, and Saint Vincents Cancer Center, all in New York. He held academic positions as Assistant Professor in the Department of Medicine at Mount Sinai School of Medicine and New York Medical College.
Roger received his undergraduate degree magna cum laude from Brown University in Providence, RI with honors in American Literature. He also received his medical degree from Brown University School of Medicine and completed his internship and residency at Harvard’s Beth Israel Hospital in Boston, MA. He completed his fellowship at Memorial Sloan-Kettering Cancer Center in hematology and oncology. He graduated with an MBA from Columbia University in New York.
Ronni P. Solomon, Esq., serves as executive vice president and general counsel at ECRI Institute, an independent, non-profit organization that focuses on improving the safety, quality and cost effectiveness of healthcare. The Institute brings the discipline of applied scientific research to discover which medical procedures, devices, drugs, and processes are best. Solomon has developed and led many innovative ECRI Institute initiatives on patient safety and quality that are widely used by thousands of hospitals, health systems, and provider organizations.
Susan Cummins Caputo BSN, MPA received her BSN at Molloy College and MPA at the New School for Social Research.
Ms. Caputo started her nursing career at Columbia Baby Hospital. She then went to MSKCC where she worked in Pediatric Oncology. Ms. Caputo went to North Shore Hospital as the Coordinator of the Pediatric Hematology and Oncology Department.
With children's survival rates improving she became interested in moving complex care to the home setting.
The past 25 years Ms. Caputo has worked in the homecare and hospice field. She has served in Clinical Sale and operations in leadership positions.
Ms. Caputo is currently the Senior VP of Business Development at VNSNY.
Viren Mehta, PharmD, MBA, Managing Member, founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years. Gather Health is Viren's new initiative to empower patients while enhancing physician productivity. Gather Health brings together providers (physicians, nurses, dietician, exercise therapist and others) and patients' social network (other patients, friends and family), enabling patient to get real-time and active resources and motivation from this team that improves outcomes. Physicians are able to see more patients due to the efficiencies fostered by the GH triage engine. Gather Health is headquartered in Hong Kong, with operations in Beijing, Mumbai and New York. Viren's biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. Viren’s philanthropic work in ecology and education through viram foundation includes an active board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA). Viren began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve superior growth while enhancing access to healthcare innovations.
Mr. Friedman has over 40 years of health care investment banking and research experience. He joined Northeast Securities as a director in February, 2010 from Burnham Securities, where he had been the co‐head of their health care investment banking practice from 2003 to 2010. Prior to joining Burnham, Mr. Friedman was with Dominick & Dominick, where he ran their healthcare practice. Mr. Friedman spent seven years with Flemings, the British merchant bank, where he headed the health care industry group, working extensively with both U.S. and international healthcare companies.
His career includes tenure at Deutsche Morgan Grenfell, where he served as Managing Director, responsible for international healthcare banking transactions; at Prudential Bache Capital Funding, where he was hired as Managing Director to start and manage its Healthcare Corporate Finance Group; at Montgomery Securities, where he was a General Partner and Co‐Founder of Montgomery Medical Ventures, and at L.F. Rothschild Unterberg Towbin, where he was a First Team Institutional Investor ranked hospital supply medical device analyst.
During his career Mr. Friedman has represented and worked with numerous leading US and European Medical Device companies including such companies as: Bausch & Lomb, Baxter International, B Braun Melsungen AG, Beecham Plc, Beiersdorf AG, ConvaTec Inc, Fresenius-Kabi AG, Instrumentarium OY, Intergra Life Sciences Inc, L'Oreal, Mallinckrodt Inc, Merit Medical Systems, Seton Healthcare Group Ltd.Teleflex Inc., Warner Lambert and Wyeth.
Mr. Friedman has served as a member of the Board of Directors of: MaxiCare Health Plans, Inc., Alta Bates Hospital and Health Care Corporation (Berkley, CA), The Mount Zion Hospital and Medical Center (San Francisco), and The Health Plan of California. He is a member of the American Hospital Association ("AHA"), The Hospital Financial Management Association("HFMA") and a founding member of The American Society of Parenteral and Enteral Nutrition ("ASPEN) as well as a Fellow of The Institute of Directors in London.
M.B.A. Finance and Marketing, Wharton Business School
B.A. Political Science, University of Pennsylvania
Dr. Ilyayev Received his training from NY Methodist Hospital and Memorial Sloan Kettering Hospital in Manhattan. He is in the forefront of continuing education, always looking for new medical breakthroughs to help his patients.
Dr. Ilyayev started his HouseCall MD practice right after completing his residency. He realized that there were elderly homebound patients who have not seen a doctor in years. He also realized that by seeing these patients in their home, this would decrease the rate of hospitalizations thereby doing his role in decreasing our national healthcare related costs.
Dr. Erik Ilyayev’s positive attitude and self-motivation is the reason he is booked one month in advance.
Dr. Peter Kash Ed.D/MBA has been in the field of biotechnology for over almost 30 years helping fund more than a dozen biopharmaceutical companies several with FDA approvals. Currently, he is Managing Director at Castle Hill Capital Partners and Vice-Chairman of TargImmune Therapeutics AG.
Besides a BS in Management Science and an MBA in Finance he also holds a Doctorate in Education from the Azrieli School of Yeshiva University. He has served as an adjunct Professor of Entrepreneurship at the Wharton School of Business, and has been a Visiting Professor at Nihon University in Tokyo Japan and in 2015 as a Visiting Professor at Hebrew University in Jerusalem. He has authored several books distributed in more than 30 countries, his most recent release is Take Two Tablets Medicine from the Bible.
A founding partner of CTSW and managing partner of the firm, Jerry Cohen has been engaged in business and commercial law for over thirty years. As a business attorney, Jerry handles corporate, financial, commercial and intellectual property transactions. Bringing both legal and business experience to balancing risk, reward, and the legal ramifications of business decisions, Jerry counsels clients on the best ways of achieving their business goals.
Often in the role of a company’s day-to-day advisor on legal and business affairs, Jerry provides strategic business advice to public and private corporations, partnerships and limited liability companies. Jerry advises clients in a wide range of transactions, including strategic alliances, joint ventures, licensing, marketing and distribution arrangements, acquisitions, divestitures, restructurings and financings.
His practice includes clients in technology, life sciences, furniture and home furnishings, financial institutions, and fast-growing emerging and entrepreneurial businesses.
Jerry co-founded and served as General Counsel and Executive Vice President to a large corporation before returning to the full-time practice of law. He also previously worked at the law firm Botein Hayes & Sklar.
Jerry is on the Board of Governors of WithIt, the Women’s Leadership Development Network, an organization in the home and furnishings industries that promotes the professional advancement of women. Jerry has been included the Super Lawyers publication every year since 2013.
To Be Announced
This event starts on February 12th at 5:00 PM.
On February 12th & 13th, 2018, YJP will be hosting its CEO Healthcare Symposium. Featuring speakers from the hospital, insurance, biotech, pharma, medical device, medtech, senior living, and home care sectors, this event will bring together top executives from across the healthcare spectrum to discuss the current and future market trends that we are seeing in the industry.
The breakout sessions, featuring our signature YJP format for maximum interaction and value, will focus on topics such as:
-The Future of Post-Acute Care
-Investing in Healthcare
-Positioning Your Organization for the Future
-Advances in Immuno-Oncology
-Transitioning to Value-Based Care
...and many more!
Join us for two days of stimulating conversation, gourmet food and drink, and high-level networking with the top names in healthcare.